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BACKGROUND 
History and epidemiology 
von Hippel-Lindau disease (vHL) (OMIM number 193300) is a rare 
hereditary disease with an autosomal dominant mode of inher-
itance. Predisposed individuals are at lifelong risk of developing 
benign and malignant tumors. The most common manifestations 
of vHL are hemangioblastomas (hbs) of the central nervous sys-
tem (CNS), kidney cysts and renal cell carcinoma (RCC), pheochro-
mocytoma (pheo), and pancreatic cysts and neuroendocrine tu-
mors (PNETs). The characteristic vascular tumors, of the retina 
were first described in the 1870-90’s and were named “angioma-
tosis retinae” by the German ophthalmologist  Eugene von Hippel  
 
in 1911 [1]. The Swedish pathologist, Arvid Lindau discovered the 
association between von Hippel’s retinal lesions and hbs of the 
cerebellum, but also RCC, pancreatic, and epididymal cysts, which 
he published in 1926 [1]. Dr. Lindau further described the disease 
to be familial, and the Danish ophthalmologist Hans Ulrik Møller 
suggested the autosomal dominant mode of inheritance in 1929 
[2]. The first clinical diagnostic criteria were suggested by Dr. 
Melmon and Dr. Rosen in 1964 [3], and form the basis of cur-
rently used international criteria [4-6]. The prevalence of vHL is 
estimated to be between 1 in 39,000 to 1 in 91,000 individuals 
and the birth incidence to be between 1 in 36,000 and 1 in 45,500 
live births in different populations [7-10]. 
 
Pathogenesis 
The VHL tumor suppressor gene 
The VHL tumor suppressor gene was mapped to chromosome 
3p25-p26 through linkage-studies in 1988 [11], and identified by 
positional cloning in 1993 [12], which made molecular genetic di-
agnosis possible. The VHL gene consists of three exons, and en-
codes two isoforms of the VHL protein (pVHL) due to alternative 
initiation of translation at codon 54 [6, 13]. The longest isoform 
p30 is 213 amino acids in length, while p19 is 160 amino acids [6, 
12, 13]. Both isoforms have tumor suppression activity [14] and 
are expressed in adult human tissues at different tissue-specific 
levels [13]. The pVHL has a comprehensive range of functions in 
essential cellular pathways. The most important is its down-regu-
lation of the expression of a group of transcription factors, Hy-
poxia Inducible Factors (HIFs), as seen in Figure 1. Without func-
tional pVHL, the HIFs are not degraded, but are instead 
translocated to the nucleus where they initiate gene transcription 
of hundreds of target genes. Many of these promote angiogene-
sis, anaerobe metabolism, erythropoiesis, and cell proliferation 
such as Vascular endothelial growth factor (VEGF), Glucose trans-
porter 1 (GLUT-1), Erythropoetin (EPO), Transforming growth fac-
tor  (TGF), and Epidermal growth factor receptor (EGFR) [6, 
13]. The binding of pVHL to HIF-α subunits requires oxygen, as the 
HIF-subunits need to be hydroxylated by prolyl hydroxylases using 
oxygen as a co-substrate in order to be recognized [13]. Lack of 
functional pVHL is equivalent to hypoxic cellular conditions, which 
explains the predisposition to vascular tumors. 
pVHL also has several HIF-independent functions, many of which 
are still being discovered. The protein plays an important role in 
assembly of the extracellular matrix through regulation of fibron-
ectin and collagen IV [6, 13]. Furthermore, pVHL has been shown 
to stabilize microtubules and modulate primary cilia formation [6, 
13].  
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Figure 1: pVHL regulation of HIFs 
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Inspired by figure 3 in [13] 
Under normal circumstances, the wild type pVHL (VHL) interacts 
with Elongin B (EB) and Elongin C (EC) to form the VBC-complex 
that in conjunction with CUL2 and RBX1 functions as an E3 ubiqui-
tin ligase. pVHL is responsible for recognizing the HIF1 and 2 α-
subunits (HIF- α), which are then marked for proteosomal degra-
dation by ubiquitination,  thereby suppressing HIF downstream 
functions [6, 13]. 
VEGF= Vascular Endothelial Growth Factor, GLUT1: Glucose Trans-
porter 1 
 
pVHL consists of two major functional domains, the β-sheet do-
main which binds HIF-α subunits and the α-helix-domain which is 
primarily responsible for Elongin B and C binding [6]. To date 
more than 700 VHL mutations have been identified, located 
throughout all three exons, although no pathogenic mutations 
have been described corresponding to the first 54 amino acids [6, 
15, 16]. Worldwide, more than half of VHL germline mutations 
are missense mutations, while large deletions, frameshift and 
nonsense mutations each account for more than 10% [6]. Curi-
ously, VHL germline mutations are also responsible for recessively 
inherited polycythemias. The most well-known is Chuvash polycy-
themia resulting from a homozygous R200W mutation that 
causes only polycythemia, but no increased risk of vHL-related tu-
mor development [6, 13]. 
 
vHL-related tumorigenesis 
vHL-related tumor development is in accordance with Knudson’s 
“two-hit-model” of tumorigenesis [17-24]: vHL patients are born 
with a germline mutation in one copy of their VHL gene in all the 
cells of the body – “the first hit”. Somatic mutation in the other 
copy of the VHL gene – “the second hit” – initiates tumor devel-
opment from that particular cell [17]. Some types of mutations 
result in lack of functional pVHL, while other types leave the cell 
with varying degrees of residual activity [6]. But, even though bi-
allelic VHL inactivation and the resulting activation of HIF and its 
targets seem to be necessary for early vHL tumor development, 
other activating factors are also needed for initiation of tumor 
progression [18, 25].  
The two-hit mechanism of VHL inactivation also applies to some 
of vHL-related tumors’ sporadic counterparts. In sporadic RCCs, 
biallelic VHL inactivation is a key event, and has been reported in 
up to 74% of tumors and in early tumor stages [26-29]. The tu-
morigenic pathways have not been as thoroughly investigated in 
sporadic CNS hbs, but some studies have suggested that the VHL-
HIF pathway plays a smaller role, as only up to 50% of CNS hbs 
have been shown to have inactivation of both VHL alleles [19, 30-
32]. Further, the mechanism seems to be even rarer in sporadic 
pheos [33, 34]. 
 
Clinical features of vHL 
VHL mutation-carriers are predisposed to develop a wide variety 
of cysts and tumors (Table 1). Patients typically develop their first 
manifestation in their twenties [35-37], and the penetrance of 
vHL has been reported to be almost 100% at age 60 years [7, 35]. 
The first manifestation is most often a CNS or retinal hb (in 
around 40% and 25%, respectively), which are also the most com-
mon manifestation types [7, 35, 37, 38]. vHL-related tumors may 
remain asymptomatic for years, but can cause severe sequelae or 
even death. Retinal hbs entail a substantial risk of vision loss due 
to retinal detachment or bleeding, and are in most cases treated 
with photocoagulation or cryotherapy at diagnosis [39, 40]. CNS 
hbs can cause devastating neurological complications, as can the 
surgical treatment in itself [38, 41-44]. The timing and surgical ap-
proach depends on many factors, especially the location of the tu-
mor, size, growth rate, and symptom development [45-47]. Early 
removal of asymptomatic hbs may be warranted in tumors with 
rapid growth patterns [46, 48]. 
 
vHL patients may develop clear cell RCC as well as multiple kidney 
cysts, which can have malignant potential, and should be fre-
quently monitored [23, 97]. RCCs are typically asymptomatic until 
they have metastasized or reached a size that requires radical ne-
phrectomy. If caught at early stages, RCCs can be monitored and 
removed with nephron-sparing surgery when they reach 3 cm 
with minor risk of metastasis [98]. Small RCCs may also be treated 
with ablation therapy with minimal loss of functional kidney tis-
sue [99]. vHL patient are also at substantial risk of pancreatic cyst-
development, which can be found in up to 70% of patients [100]. 
Other vHL-related manifestations include serous pancreatic ade-
nomas and PNETs, which require expert care as they can become 
malignant [100]. Endolymphatic sac tumors (ELST) can cause sud-
den and permanent hearing loss at even early stages, and can be 
very hard to diagnose [89, 101, 102]. Cyst adenomas of the epidi-
dymis may develop in men, and cysts of the broad uterine liga-
ment in women, although the reported incidences are low [103]. 
 
Phenotypic expression of vHL is variable and hard to predict. Sev-
eral genotype-phenotype correlations have, however, been es-
tablished. Clinically, vHL can be characterized based on the ab-
sence or presence of pheos in the family into type 1 or type 2, 
respectively [9, 60, 104-107]. Though there are exceptions to the 
rule, type 1 is predominantly caused by VHL mutations truncating 
the protein product, while type 2 is most often caused by mis-
sense mutations that in most cases leave an abnormal, but partly 
functional protein product [6, 36, 60, 104, 105, 107, 108]. Type 2 
has been further subdivided into type 2A with a low risk of RCC, 
type 2B with a high risk of RCC, and type 2C with pheo as the sole 
manifestation type [60, 106]. Other genetic factors have been 
shown to contribute to the phenotypic variation among vHL pa-
tients. Large germline deletions also involving the VHL-adjacent 
gene BRK1 (C3orf10/HSPC300), which functions as an actin regu-
lator, are associated with significantly lower RCC and retinal hb 
risks [109-112].
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Table 1: Frequencies of typical vHL associated manifestations and of vHL patients among patients with specific manifestations 
Manifestation 
Frequency of vHL pt with the 
manifestation type1 
(No. of vHL pt. of total no. of pt 
in the included cohorts, range: 
lowest-highest frequency in the 
included cohorts) 
Ref 
Average age of onset  
(N= Total no. of vHL pt re-
ported in the included 
studies with the manifes-
tation, range: lowest-high-
est age in the included co-
horts ) 
Ref 
Frequency of vHL pt among 
pt with the manifestation  
(N= No. of pts. with the 
manifestation, range lowest-
highest frequency in the in-
cluded cohorts) 
Ref 
Retinal hb 
52 %  
(1,716 of 3,294, range: 15-73%) 
[7, 9, 35-
37, 43, 47, 
49-62] 
25-37 years 
(N= 980, range: 9-84) 
[36, 49, 
50] 
Median: 46 % 
(N=145, range: 31-81 %) 
[47, 63-
65] 
 
Cerebellar hb 
49 % 
(786 of 1,598, range: 35-79 % ) 
[7, 35-37, 
43, 45, 47, 
52, 53, 55, 
57, 58, 66, 
67] 
29-30 years 
(N= 484, range: 13-61) 
[35, 36, 
66] 
CNS hb (all locations):  
Median 18.5 % 
(N= 563, range: 4-57 %) 
[41, 63, 
68-71] 
Spinal hb  
27 % 
(392 of 1,472, range: 7-53 %) 
[7, 36, 37, 
39, 43, 45, 
47, 52, 53, 
57, 58, 67] 
33-34 years 
(N= 186, range: 8-60) 
[35-37] 
Brainstem hb 
16% 
(65 of 413, range 4-22 %) 
[37, 47, 52, 
54, 58, 67] 
25-38 years 
(N= 53, range: 16-60) 
[37, 72, 
73] 
Cerebral hb 
4 % 
(26 of 586, range: 1-7%) 
[37, 43, 47, 
57, 67] 
29 years 
(N=1) 
[37] 
RCC 
30 % 
(532 of 1,784, range: 5-86%) 
[7, 35, 37, 
45, 53-58, 
60, 62, 66, 
69, 73] 
40-45 years 
(N= 247, range: 20-69) 
[35, 36, 
66] 
< 5 % [58] 
Renal cysts 
42 % 
(99 of 231, range: 10-89 %) 
[37, 45, 53-
56, 58, 64, 
69] 
34-39 years 
(N= 51, range: 12-64) 
[7, 37, 
64] 
- - 
Pheo 
16 % 
(403 of 2,546, range: 0-32%) 
[7, 35-37, 
43, 45, 47, 
53-55, 57-
62, 74, 75] 
20-29 years 
(N= 240, range: 5-62) 
[35, 36, 
75] 
Sporadic: 2-11 % 
(N= 813) 
Familial: 15-34% 
(N= 236) 
[76-83] 
Pancreatic 
cysts 
21 % 
(178 of 831, range: 15-35 %) 
[37, 43, 45, 
53-56, 58, 
60, 69, 84] 
29-37 years 
(N=45, range: 12-63) 
[7, 37, 
64] 
- - 
PNET 
10 % 
(170 of 1,656, range: 1-17 %) 
[37, 45, 55, 
59, 60, 84-
86] 
32-38 years 
(N=143, range: 16-68) 
[85-87] 
1 % 
(N= 101) 
[88] 
ELST 
11 % 
(67 of 583, range: 3-16 %) 
[45, 47, 53, 
56, 89-91] 
22-40 years 
(N= 69, range: 11-63) 
[90-92] 
5-15 % 
(N= 74) 
[93-95] 
 
Epididymal cyst 
adenoma 
25 % 
(73 of 287,  range 3-32 %) 
[37, 43, 47, 
53] 
24 years 
(N=6, range: 10-37) 
[37] - - 
 
Modified from table 1 in [96] No.= Number, Pt= Patients, RCC= Renal Cell Carcinoma, Hb= Hemangioblastoma, Pheo= Pheochromocy-
toma, PNET= Pancreatic Neuroendocrine tumor, ELST= Endolymphatic sac tumor, Ref= references 
1 Based on the studies of vHL cohorts (> 5 pt) reported in the literature. To avoid selection bias due to geno-phenotype correlations, co-
horts selected based on a specific genotype or manifestation were excluded. It should be noted that the frequencies of specific manifes-
tations  vary with the age distributions in the individual cohorts.
  DANISH MEDICAL JOURNAL   4 
The median life expectancy for vHL patients was reported to be 
49 years in 1990 [35]. Improved diagnostic techniques and treat-
ment options, as well as the widespread use of prophylactic sur-
veillance are expected to have improved the life expectancy, alt-
hough this has not been directly assessed in an unselected vHL 
cohort. The main causes of death among vHL patients have been 
reported to be CNS hb (41-60%) and RCC (27-47%) [7, 35, 38].  
Surveillance guidelines 
The mainstay of vHL management is close surveillance from early 
childhood and surgical treatment of vHL related tumors. Cur-
rently, no preventive systemic therapies exists, and chemother-
apy is used only as a second line treatment in cases of inoperable 
tumors, often only with moderate drug responses [113-116].  
Table 2 gives an overview of the Danish vHL surveillance recom-
mendations [96]. It is important to stress, that surveillance rec-
ommendations predominantly are meant as guidelines and are 
especially applicable for asymptomatic VHL mutation-carriers. 
Once patients have symptoms or diagnosed manifestations, 
prophylactic screening should be adjusted accordingly. The Dan-
ish surveillance recommendations correspond to international 
guidelines [4, 41, 71, 102, 117, 118].  
Surveillance can cause considerable psychological strain on the in-
volved vHL families [119, 120], as well as large expenses for the 
health care system [71]. It is widely accepted that surveillance im-
proves morbidity and mortality [41, 43, 57, 70, 118, 121, 122], but 
definite evidence has yet to be reported. Current recommenda-
tions are based on best clinical judgment and experience. Besides 
the age-differentiated initiations, the recommendations are iden-
tical for all patients regardless of individual factors. Better 
knowledge about the natural course of the disease and well as in-
fluencing factors could help individualize surveillance. 
Table 2: Danish vHL surveillance recommendations 
From 0 to 4 years 
• Annual clinical examination by a paediatrician 
• Annual ophthalmoscopy in dilation 
From 5 to 14 years of age 
• Annual clinical examination by a paediatrician 
• Annual ophthalmoscopy in dilation 
• Annual plasma-metanephrine and plasma-nor-
metanephrine  
• Annual hearing examination in a department of audiology 
• 1 x Magnetic Resonance Imaging (MRI) scan of the CNS 
and 
• 1 x Ultra Sound (US) of the abdomen (Imaging optimally in 
the age interval 8-14 years of age) 
From 15 years of age 
• Every second year: MRI scan of the CNS including the inner 
ear 
• Annual ophthalmoscopy in dilation 
• Annual neurological examination (by a neurologist or a 
neurosurgeon) 
• Annual US/MRI of the abdomen (kidneys, adrenal glands, 
pancreas, liver) 
• Annual plasma-metanephrine, plasma-normetanephrine, 
and plasma-chromogranin A 
• Annual hearing examination in a department of audiology 
Based on the surveillance recommendations given in [96]. The 
guidelines are written by the national vHL coordination group (See 
Appendix 1 for a description of the group and its functions). 
vHL diagnosis: clinical criteria and genetic analysis 
A clinical vHL diagnosis can be made using the diagnostic vHL cri-
teria, which vary slightly between countries (Table 3). According 
to the Danish criteria, an individual with a negative family history 
but with any two vHL-related manifestations by definition has 
clinical vHL [96]. In the majority of international criteria, all based 
on Melmon and Rosen’s original criteria, at least one of the mani-
festations must be a hb (CNS or retinal) [3, 4, 6, 123]. 
Genetic testing is of great importance, especially for pre-sympto-
matic detection of mutation-carriers in affected families [119, 
124]. The detection rate of a VHL germline mutation in patients 
with clinical vHL is up to 95-100% when a combination of direct 
sequencing, Southern blotting, Fluorescence In Situ Hybridization 
(FISH), and/or Multiplex Ligation-dependent Probe Amplification 
(MLPA)is used [74, 124-126]. The frequency of VHL mutations 
among clinically affected patients depends on the phenotypic 
spectrums in the tested cohorts [126]. 
Table 3: vHL clinical diagnostic criteria 
 Danish criteria [96] International criteria [3, 
4, 6, 123] 
Positive fam-
ily history/ 
VHL mutation 
1 vHL-related manifesta-
tion 
1 vHL-related manifesta-
tion 
Negative fa-
mily history 
At least 2 vHL-related  
manifestations 
2 hb (CNS or retinal) or 
At least one hb (retinal 
and/or CNS) and a visceral 
lesion 
vHL-related 
manifesta-
tions included 
in the criteria Retinal hb 
Hb in cerebellum, the me-
dulla oblongata, or the 
spinal cord 
ELST 
RCC 
Pheo, paraganglioma, 
and/or glomus tumor 
PNET and/or multiple  
pancreatic cysts 
Retinal hb 
CNS hb 
RCC 
Pheo 
PNET 
ELST 
Pancreatic cysts* 
Epididymal cystadeno-
mas* 
* These manifestations are not included in all criteria, hb= heman-
gioblastoma, RCC: renal cell carcinoma, PNET: Pancreatic Neuro-
endocrine tumor, Pheo= Pheochromocytoma 
 
National registers in Denmark 
National Health Registers 
The Danish health care system is tax-funded with free access to 
medical care. Every contact with a health provider is systemati-
cally registered and information from different registers can be 
linked to an individual using a unique identification number (the 
Civil Registration System (CRS)). This provides exceptional oppor-
tunities for genetic epidemiology studies, as information about 
family relations is also available in the CRS. See Appendix 2 for de-
tailed information. 
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Background of the vHL Research Database 
In the 1930-1940’s Dr. Kai Albrechtsen collected information 
about Danish vHL families, which are now part of the national ar-
chives and kept at the Department of Cellular and Molecular 
Medicine (ICMM). Dr. Anette Møller Jensen did a follow-up study 
in the 1980-1990’s, where she interviewed affected families, col-
lected hospital records, death certificates, and family information. 
In the same period, Dr. Thomas Rosenberg started the first na-
tional vHL Register as part of the Danish Family Archive for Ge-
netic Eye Diseases at the National Eye Clinic (which later moved 
to the Kennedy Center, Rigshospitalet in Glostrup) [127] with the 
purpose of ensuring that Danish vHL patients were offered proper 
surveillance and family diagnosis. In 2008 our group started the 
vHL Research Database and included both information from the 
vHL Register and from Dr. Albrechtsen’s and Dr. Møller Jensen’s 
research. We updated the pedigree information for 31 families 
and added an additional 12 families. From 2008-2016, we have in-
terviewed the affected living individuals and collected hospital 
records to document all vHL examinations and manifestations 
that each affected family member had ever had. The vHL Re-
search Database now contains detailed well-documented clinical 
information and pedigrees of all vHL families ever identified in 
Denmark going back as far as ten generations in the largest fami-
lies. In May 2012, the Danish vHL Coordination Group established 
the official national vHL Database as a primarily clinical tool for di-
agnostic and management purposes [96, 127]. This database in-
cludes basic clinical information about Danish vHL patients as well 
as all individuals genetically tested for VHL mutations. It is contin-
uously updated when new vHL families are diagnosed at the clini-
cal genetic departments in Denmark. 
Main challenges of vHL management 
• vHL displays considerable phenotypic variability, both 
between different families, but also within the same 
family [7, 35, 43, 128]. It is almost impossible to predict 
a patient’s most likely phenotype, such as which organs 
will be affected, how high is the risk of development of 
specific tumor development at certain life phases, or 
how fast will the tumors grow. Not knowing what to ex-
pect from their disease can cause uncertainty and dis-
tress for vHL families [119, 129, 130], and complicates 
counseling and clinical management. 
• We hypothesize that vHL is underdiagnosed in Den-
mark, and that the vHL diagnosis is often delayed or un-
recognized. Compared to international prevalence esti-
mates, the Danish prevalence of 67 living diagnosed 
individuals in 2008 is low. Undiagnosed vHL families are 
not offered genetic counselling and asymptomatic ge-
netic testing. They do not attend prophylactic surveil-
lance and are at risk of permanent complications or 
death, which might have been prevented. 
AIMS 
The main aim of this PhD study was to improve the understanding 
of factors that complicate the diagnosis, genetic counseling, and 
surveillance of vHL families through investigation of: 
  
Phenotypic variability: Paper I and II 
How is the development of new manifestations among VHL muta-
tion-carriers influenced by: 
• Age 
• Genotype 
• Sex 
• Pregnancy 
• Tumor location  
 
vHL survival: Paper III 
• How has the survival of VHL mutation-carriers devel-
oped over time compared to siblings without vHL and 
the general population? 
• How is survival influenced by sex, genotype, and surveil-
lance attendance? 
 
vHL diagnosis: prevalence, incidence, and penetrance: Paper IV 
• What is the prevalence and incidence of vHL in Den-
mark?  
• Is vHL underdiagnosed in Denmark? 
• What is the penetrance of vHL in a national cohort? 
 
MATERIAL AND METHODS 
Study designs 
Papers I, II, III, and a part of IV are based on retrospective national 
cohort studies. Paper IV also includes a register study of Danish 
health registers (Table 4). 
Study populations and data collection 
The Danish vHL cohort comprises 165 individuals identified as 
having vHL in Denmark (Figure 2). We had detailed clinical infor-
mation concerning 150 of them. The remaining fifteen were all 
living individuals diagnosed with vHL, who had declined study par-
ticipation (12 individuals) or whom we had not contacted (three 
individuals). 
 
Paper I and II: First round of study inclusion  
The initial cohort consisted of carriers of a pathogenic VHL 
germline mutation who were alive and resident in Denmark on 1st 
of June 2008 and who attended surveillance. We identified 59 
mutation-carriers from 25 unrelated families and contacted 54 
(from 22 families). We did not contact five individuals who had 
previously refused research participation. All 54 contacted indi-
viduals consented to participate (90%, 54 of 59). Two individuals 
were excluded from the analysis, as they were newly diagnosed 
and did not yet started their surveillance. The parents consented 
on behalf of children under 18 years. 
 
Paper III and IV: Follow-up and second round of study inclusion  
From 1st of January 2014 to the 1st January 2016, the 52 already 
included VHL mutation-carriers were followed-up. We identified 
an additional 31 living VHL mutation-carriers from six included 
and nine new families, who had been diagnosed between 2008 
and 2016. Overall, we contacted 88 living individuals including the 
52 individuals from 2008 and three individuals from two families 
not contacted in 2008. Three individuals had, via family members, 
asked not to be contacted. Overall, 76 individuals consented, 
while 12 declined. We found 74 deceased patients from 18 in-
cluded and four new families. We further contacted 11 individuals 
(seven families) diagnosed with clinical vHL without an identifia-
ble VHL germline mutation, and nine consented. We found 21 in-
dividuals with a benign VHL variant (N=16) or a variant of un-
known significance (VUS) (N=5) [131]. These individuals were not 
included, as none fulfilled the clinical criteria. 
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Table 4: Overview of the papers’ designs, observation periods, and included subgroups 
 Included groups of individuals 
Paper Study design 
Study period/  
Observation time 
Exclusion criteria 
VHL mut-
carriers 
Pt. with  
clinical vHL 
without a  
detectable 
VHL mut/mut 
analysis 
First-degree  
relatives without 
vHL 
Potential vHL 
patients  
identified in 
register search 
I 
Cohort study 
Observation time: 
1st Jan 1971 –  
1st June 2008 
(1,719 person-years) 
- Deceased VHL 
mut-carriers 
 
- VHL mut-carriers 
not attending sur-
veillance 
 
- Patients with clini-
cal vHL without VHL 
mut 
N = 52 - - - 
II 
III 
Register 
based Cohort 
study 
 
Observation time: 
16th May 1841 - 
1st Jan 2016 
(6,075 person years) 
 
VHL mutation-carri-
ers born before 
2010 
N= 143 - 
N = 137 
Siblings of VHL 
mut-carriers 
(Control group) 
- 
IV 
Register 
study 
+ 
Cohort study 
Study period:  
Register study: 
1st Jan 1977 – 
10th Dec 2015 
 
Penetrance  
analysis: 
1878 – 2014 
 
Not alive in the 
study period 
N = 97 N = 9 
N =256 
All known par-
ents, siblings and 
children alive dur-
ing study period 
N = 335 poten-
tial vHL patients 
and 331 of their 
first-degree rel-
atives 
Mut-carrier= Mutation-carrier 
 
Paper III is a register study that included all deceased and living 
vHL patients born before 2010 from the families in which a patho-
genic VHL mutation had been confirmed in at least one affected 
family member. The 143 included individuals were either con-
firmed VHL mutation-carriers (N=89) or assumed mutation-carri-
ers: (a) had at least one vHL manifestation (N= 48) or (b) were ob-
ligate mutation-carriers (had affected parents/siblings as well as 
affected descendants) (N=6). 
 
For the evaluation of clinical characteristics in paper IV, we in-
cluded 106 consenting individuals (76 living and 30 deceased,  
from 39 unrelated families) who had been diagnosed with vHL 
and had been alive at some point in the study period. 
The penetrance analysis in paper IV was based on data about 150 
vHL patients’ first manifestation diagnosis, their first manifesta-
tions had been diagnosed between 1878 and 2014. 
Descriptions of subgroups of the vHL cohort have previously been 
published: [37, 89, 132, 133] 
 
Data collection for the included vHL patients: 
The process of data collection is illustrated in Figure 3. 
 
All consenting individuals in papers I, II, and IV were interviewed 
(the parents on behalf of children under 18 years, and living rela-
tives in the cases of deceased patients) and gave us permission to 
collect their hospital records concerning all vHL-related examina-
tions and manifestations throughout their lives. This was initially 
done for the 52 included individuals in 2008. During their follow-
up in 2014-2016, interviews were repeated and additional hospi-
tal records collected. During the second round of inclusion/fol-
low-up, the consenting individuals over 18 years gave a blood 
sample for genetic analysis. From the vHL Research Database we 
obtained hospital records and/or documented patient/family in-
formation for 55 deceased individuals. We interviewed the living 
relatives of an additional 19 deceased individuals for whom we 
also collected hospital records. 
 
First-degree relatives without vHL 
We drew the families’ pedigrees using the pedigree software 
Progeny (Progeny Genetics LLC, Florida, USA). Information about 
familial relations was obtained during patient interviews (includ-
ing records of interviews with now deceased family members per-
formed 1987-1993), the Civil Registration System (CRS)), and 
Church records and Population censuses in the cases of individu-
als who had died or emigrated before the start of the CRS in 1968.  
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In paper III we included 137 siblings without vHL (they had either 
been tested negative for the family’s VHL mutation (N=59) or did 
not have any vHL-related symptoms (N=78)) from all known fami-
lies in which the causative VHL mutation had been identified. 
Figure 2: Flowchart of inclusion of the Danish vHL cohort 
Identified 
living 
vHL patients
2008 20162014
Identified
deceased
vHL patients
Retrospective collection of 
data about the included
subjects’ entire lifetimes
Study start Study end
• 61 VHL mut-carriers
• 2 Mut Neg vHL pt
• 4 clinical vHL pt never gene 
tested
Total number
of identified
vHL pt: 165 
(43 families)
Total number of 
living vHL pt: 91
Total number of 
deceased vHL pt: 
74
Newly diagnosed vHL patients
7 vHL pt
died during study
Overall: 
76 living +
30 deceased
vHL pt
• 59 VHL mut-carriers
• 8 Mut Neg vHL pt
• 52 living VHL mut-
carriers
• 45 (19 living + 26 deceased) VHL mut-carriers
• 9 (5 living + 4 deceased) Mut Neg vHL pt  
Included
vHL patients
Paper I and II
Paper III and IV
Total number
of included
vHL pt: 106
(39 families)
• 31 VHL mut-carriers
• 1 Mut Neg vHL pt
• 6 VHL mut-carriers
• 1 Mut Neg vHL pt
INITIAL STUDY
FOLLOW-UP STUDY
Follow-up and new data collection
This chart shows the flow of vHL patients between different cohort subcategories: living, deceased, and included in the study. Study in-
clusion refers to individuals who gave their consent to active study participation: 1) Interviews, 2) permission to collect all of their hospi-
tal records regarding vHL, and 3) a blood sample for genetic testing. 
VHL mut-carrier: Carrier of a pathogenic VHL mutation. Mut Neg vHL pt: Patient fulfilling the clinical diagnostic vHL criteria without an 
identifiable VHL mutation 
 
Figure 3: Method of data collection 
First inclusion round
54 living VHL mutation-carriers
• Patient interviews
• Retrospective evaluation of 
all medical records
2008
2014
2016
Follow-up
52 living and deceased VHL
mutation-carriers
• Subsequent interviews
• Evaluation of medical records 
2008-2016
• Blood sample for genetic 
testing
Second inclusion round
54 additional living and deceased vHL patients
• Patient interviews
• Retrospective evaluation of all medical records/ vHL
Database registrations
• Blood sample for genetic testing
Additional data included
• Paper III: The Causes of Death Register, 
autopsy reports, and death certificates
• Paper IV: National Health Registers
2 individuals 
withdrew 
their consent
106 included 
vHL patients
 
 
  
 DANISH MEDICAL JOURNAL   8 
Individuals identified through Danish national health registers 
We used the following national registers (see Appendix 2 for de-
tailed descriptions): The Civil Registration System, The Patient 
Register, the Cancer Register, the Pathology register, and the 
Causes of Death Register. 
In paper III, we utilized the Causes of Death Register to obtain in-
formation about date and specific causes of death. For patients 
who died before 1970, we used death certificates, medical rec-
ords describing the time around the death, and autopsy reports. 
In the register study in paper IV we identified and included 335 in-
dividuals who might fulfill the clinical diagnostic vHL criteria [96] 
based on their registered ICD (International Classification of Dis-
ease)-codes in the Patient Register and the Cancer Register. We 
chose the ICD-codes used in the register search, based on a pilot 
study of known vHL patients whose registrations were compared 
to their hospital records. We reviewed the full medical histories 
of the 335 identified individuals (i.e. all diagnostic and pathologi-
cal codes ever registered about each individual in the Patient reg-
ister, the Cancer register, the Pathology register, and the Causes 
of Death Register) to confirm the diagnoses of their vHL-related 
manifestations. Using the CRS, we identified 331 first degree-rela-
tives of 68 individuals who were assessed to fulfill the vHL clinical 
diagnostic criteria (assumed vHL patients). We evaluated the full 
registered medical histories of 205 of these relatives as well. 
 
Information from Statistics Denmark 
Statistics Denmark provides descriptive statistical information 
about the Danish population [134]. For paper III we obtained sex- 
and age-specific mortality rates for Danish birth cohorts born be-
tween 1900 and 2014. From here, we collected information about 
the size of the population and number of live births in our chosen 
incidence period of 1945- 1964 for paper IV.  
Genetic analysis 
We confirmed the included families’ VHL germline mutations in at 
least one affected individual. A new mutation was found in a pa-
tient with clinical vHL who had not been genetically tested before. 
We counseled and performed genetic testing in seven first-degree 
relatives who had not been tested but expressed interest in such 
during a family interview.  We found the family’s VHL mutation in 
one 18-year old asymptomatic child of an affected mother, but 
not in the other six tested individuals (2 children and 4 siblings of 
affected vHL patients). 
 
Sanger sequencing and Multiplex Ligation dependent Probe Am-
plification (MLPA) 
Genomic DNA was purified from peripheral lymphocytes using 
the PureGene Blood Core Kit C (Qiagen, Hilden, Germany, cat. no. 
158389) according to the manufacturer’s instructions. We looked 
for germline VHL mutations through PCR-amplification of all three 
VHL exons and exon-intron boundaries (intronic primer pairs: 
Exon 1F: 5’-AGCGCGTTCCATCCTCTAC-3’, Exon 1R: 5’-
GGGCTTCAGACCGTGCTAT-3’, Exon 2F: 5’- CAC-
CGGTGTGGCTCTTAAC -3’, Exon 2R: 5’- 
TGGGCTTAATTTTTCAAGTGG-3’, Exon 3F 5’- GTTGGCAAA-
GCCTCTTGTTC-3’, Exon 3R: 5’- AAGGAAGGAACCAGTCCTGT-3’). 
We performed direct Sanger sequencing using the ABI BigDye® 
Terminator Cycle Sequencing Kit, version 1.1 on an ABI Prism® 
3130XL Genetic Analyzer according to the manufacture’s manual. 
The sequences were visualized for evaluation using the Chro-
masPro version 1.7.6 (Technelysium Pty Ltd, South Brisbane, Aus-
tralia). 
We further looked for deletions and duplications in the VHL gene 
by MLPA analysis using the MLPA-VHL test kit (P016-C2, MRC-Hol-
land, Amsterdam, Netherlands), according to the manufacturer’s 
protocol. The results were analyzed using Coffalyzer.Net (MRC-
Holland, Amsterdam, Netherlands). 
 
In silico analysis of the identified VHL mutations 
Alamut Visual Software version 2.6 (Interactive Biosoftware, 
Rouen France) was used to confirm the pathogenicity of each 
identified VHL mutation. For further analyses, we grouped the 
mutations into two categories: 1) missense mutations and 2) 
truncating mutations (deletions, frame-shift mutations, nonsense, 
and splice-site mutations). Appendix 3 gives a full list of the in-
cluded genotypes. 
 
Data assessment and statistical analysis 
Paper I and II: 
To determine how fast new tumors developed at different stages 
of life, we used Poisson regression models to calculate age-re-
lated manifestation rates. That is, the average number of new 
manifestations diagnosed/year calculated in relation to age in 
predefined five-year intervals from 0-60 years. 95% Confidence 
intervals (CI) were based on robust standard errors (SE), which al-
lowed for heterogeneity in the manifestation rates between the 
mutation-carriers. Using hazard ratios (HR), we compared the 
manifestation rates in groups of 1) different ages, 2) tumors in 
different locations (hbs in the cerebellum and retina), 3) patients 
with different genotypes (truncating and missense mutations), 4) 
men and women, and 5) women in pregnancy and in non-preg-
nancy intervals (the women were defined as being in a preg-
nancy-interval up to five years after the estimated date of con-
ception). 
 
Paper III: 
To assess the progression in vHL survival over time, we compared 
Kaplan-Meier curves for vHL patients born at different times. The 
development was further illustrated through comparison to the 
survival of their siblings without vHL using a Cox regression model 
with birth year, sex, and vHL status (vHL patient or non-vHL sib-
ling) as co-variates. We used similar Cox regression models to 
evaluate the effects of influencing factors on the vHL patients’ 
hazard of death as well as their hazard of dying due to a vHL-re-
lated cause by a stepwise addition of multiple covariates in sepa-
rate models (birth-year, sex, genotype, and surveillance attend-
ance). The 95% CI was based on robust SE that allowed for 
heterogeneity between the families. Surveillance attendance was 
defined as regular examinations of the abdomen and/or CNS per-
formed to screen for vHL manifestations for a period of at least 
three consecutive years. 
We used a relative survival model to compare vHL survival to the 
survival of the general Danish population and estimate the mean 
remaining life-time at age ten for individuals born in different 
years. This model calculates the excess mortality due to vHL using 
mortality rates of the general Danish population as a baseline. 
Causes of death were categorized as being vHL-related or vHL-un-
related based on information given on the deceased patients’ 
death certificates, data extracted from the Causes of Death Regis-
ter, as well as autopsy records and hospital records from around 
the time of death in some cases. Deaths were assessed to be vHL-
related if a vHL manifestation, long-term or post-operative vHL-
related sequelae or surgical complications were the direct or indi-
rect causes of death. 
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Paper IV: 
We estimated vHL penetrance based on 150 vHL patients’ ages at 
their first manifestation diagnosis. We used Kaplan-Meier curves 
to calculate cumulative age-related incidences of 1) all first mani-
festations (regardless of how they were diagnosed) and 2) all first 
manifestations that were diagnosed due to symptoms. 
vHL point prevalence was calculated as the proportion of live vHL 
patients in the Danish population on 1st January 2014. Birth inci-
dence was estimated as the proportion of vHL patients born be-
tween 1945 and 1964 of the total number of live births in Den-
mark during that period. 
The level of statistical significance was set at 5% in all analyses. 
Statistical analyses were performed using SAS version 9.3 or ver-
sion 9.4 (SAS Institute, Cary, USA) or R version 3.2.5 with the 
package survival version 2.28-3 [135]. 
Ethical considerations 
The project was approved by the Danish Data Protection Agency 
(2009-41-3994) and the Regional Committees on Biomedical Re-
search Ethics (H-2-2010-012), and included individuals gave their 
written consent for participation in paper I, II, and IV. The na-
tional register search and utilization of data from the national 
Danish vHL Research Database (paper III and part of paper IV) 
were conducted as register studies that did not require consent 
from the included individuals. 
RESULTS 
In total, the 150 individuals for whom we had detailed clinical in-
formation, had 5,715 vHL-related examinations and 1,209 vHL 
manifestations diagnosed. Almost all manifestations (98%, 1,182 
of 1,209) were verified through medical records. The rest were re-
ported only by the patients themselves or family members. In the 
cases of three deceased patients, we solely had information 
about their manifestations through interviews. As the information 
was very specific, they were included in the penetrance analysis 
in paper IV. Appendix 2 and 3 show the characteristics of the in-
cluded and non-included patients’ genotypes and phenotypes. 
Papers I, II, and III: Factors influencing the vHL phenotype and 
course of disease 
Paper I and II: New manifestation development 
We found that the number of new manifestations diagnosed per 
year is not constant throughout vHL patients’ lives, but varies sig-
nificantly with age, genotype, and the anatomical location of the 
tumor. New tumor development is similar for men and women, 
and pregnancy is associated with a decreased rate of new tumor 
development. 
Through interviews and evaluation of medical records concerning 
all vHL-related hospital visits of the included 26 male and 26 fe-
male VHL mutation-carriers, we identified 2,583 examinations 
and 581 manifestations. The rate of new tumor diagnosis was 
highest in patients’ thirties with a mean rate of almost one new 
manifestation diagnosed per year (Table 5). As expected, this rate 
was significantly higher than rates in childhood and teenage 
years, but also than the rates in patients’ early twenties. The 
manifestation rate tended to decrease after patients’ thirties alt-
hough the difference was not significant. 
 
 
Table 5: Manifestation rates (new manifestations/year) for all vHL manifestations as a function of age and hazard ratios (HR) for 
comparison of age-groups and sex groups 
Age-intervals 
Both sexes 
Manifestation rates 
(95% CI) 
N= Number of  
included pt. 
Comparison of 
age-groups1 
HR (95% CI) 
p-value 
Men 
Manifestation rates 
(95% CI) 
N= Number of included pt. 
Women 
Manifestation rates 
(95% CI) 
N= Number of included pt. 
Comparison of sex-
groups 
HR (95% CI) 
p-value 
0 − 14 
0.040  
(0.022 - 0.071) 
N= 52 
0.045  
(0.024 − 0.086) 
p < 0.0001 
0.045  
(0.020 - 0.101) 
N= 26 
0.035  
(0.015 - 0.080) 
N= 26 
1.281  
(0.401 - 4.091) 
p= 0.68 
15 − 19 
0.250  
(0.126 - 0.497) 
N=39 
0.284 
 (0.122 − 0.661) 
p= 0.004 
0.232  
(0.108 - 0.495) 
N= 19 
0.269  
(0.089 - 0.812) 
N= 20 
0.862   
(0.225 - 3.297) 
p= 0.83 
20 − 24 
0.386  
(0.221 - 0.676) 
N=37 
0.439  
(0.225 − 0.854) 
p= 0.015 
0.474  
(0.217 - 1.032) 
N= 19 
0.300  
(0.144 - 0.626) 
N= 18 
1.579  
(0.541 - 4.607) 
p= 0.40 
25 − 29 
0.398  
( 0.174 - 0.911) 
N=35 
0.452  
(0.181 − 1.133) 
p= 0.090 
0.204  
(0.080 - 0.522) 
N= 17 
0.567  
(0.203 - 1.583) 
N= 18 
0.361  
(0.090 - 1.449) 
p= 0.15 
30 − 34 
0.880  
(0.570 - 1.360) 
N=32 
1 ( − ) 
1.412  
(0.841 - 2.369) 
N= 14 
0.472  
(0.278 - 0.803) 
N= 18 
2.988  
(1.424 - 6.267) 
p= 0.004 
35 − 39 
0.863  
( 0.562 - 1.326) 
N=29 
0.981  
(0.570 − 1.686) 
p= 0.944 
0.858  
(0.462 - 1.595) 
N=12 
0.867  
(0.483 - 1.558) 
N= 17 
0.990  
(0.422 - 2.323) 
p= 0.98 
40 − 60 
0.611  
(0.441 - 0.846) 
N=24 
 
0.694  
(0.423 − 1.139) 
p= 0.148 
0.572  
(0.432 - 0.758) 
N=10 
0.638  
(0.383 - 1.063) 
N= 14 
0.897 
 (0.501 - 1.606) 
p= 0.71 
Based on table 2 from paper I and table 2 from paper II. N= Number of subjects included in the age-interval. We included all manifesta-
tion types (581 manifestations). Subjects were followed from birth.  The age-groups 0-14 and 40-60 years were pooled due to low mani-
festation numbers. 
1: In the age-group comparison: the HRs are calculated using the age-group 30-34 years as the reference interval. 
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When we compared the manifestation rates for patients with 
missense mutations (N= 22) to those with truncating mutations 
(N=30), the overall manifestation rate was significantly higher for 
truncating mutation-carriers (HR=1.85, 95% CI: 1.05-3.25, p= 
0.033). This was especially due to higher rates in adulthood and 
more frequent cerebellar tumor development. For cerebellar tu-
mors, the overall rate was twice as high for truncating mutation-
carriers (HR=2.3, 95% CI: 1.01-5.08), while their overall rate of 
new retinal tumor diagnosis was less than half of the missense 
mutation-carriers’ rate (HR=0.391, 95% CI: 0.21-0.73, p=0.003). 
 
Seventeen of the included women had completed 30 pregnan-
cies. The rates of new manifestation diagnosis were lower when 
the women were pregnant compared to when they were not 
pregnant (Tabel 6). Any pregnancy effect on microscopic tumor 
precursors was not expected to be seen immediately, as progres-
sion to a radiologically detectable tumor would take time. There-
fore, we defined three pregnancy intervals of varying lengths to 
look for any long-term effects. Indeed, we found that the mani-
festation rates were significantly lower up to 5 years after con-
ception. 
 
Table 6: Effect of pregnancy on manifestation rates 
Pregnancy interval Hazard ratio (95% CI) p-value 
1 year 0.343 (0.084 − 1.402) 0.136 
3 years 0.372 (0.194 − 0.712) 0.003 
5 years 0.476 (0.239 − 0.949) 0.035 
Modified from table 1 in paper II. Thirty pregnancies among 17 
women were included in all three pregnancy-intervals (defined as 
time form estimated conception). The analysis was adjusted for 
number of manifestations at age 20 and genotype (truncating or 
missense mutation). 
 
We assessed the rate of new manifestation development sepa-
rately for only cerebellar and retinal hbs, as these were the most 
frequent vHL manifestation types (Figure 4). The high manifesta-
tion rate in patients’ thirties seems to be primarily caused by a 
significant increase in the number of cerebellar tumors. From the 
patients’ thirties to forties, new cerebellar tumor diagnosis 
reached a rate of more than one new tumor every second year 
(35-39 years: 0.57 new tumors/year, 95% CI: 0.33 – 1.00). Rates at 
younger ages (under 30 years) were significantly lower. In con-
trast, new retinal hbs were diagnosed at the highest rate in pa-
tients’ teenage years, also corresponding to a rate of about one 
new tumor every second year (15-19 years: 0.51 new tu-
mors/year, 95% CI: 0.22-0.75). Rates of new retinal hbs in early 
childhood and ages older than 25 years were significantly lower. 
Paper III: vHL survival and causes of death 
The survival of vHL patients has improved over time, and is signifi-
cantly influenced by a patient’s birth year, sex, and genotype. We 
estimate the mean life expectancy of VHL mutation-carriers born 
in 2000 to be 67 years for men and 60 years for women. RCC is 
becoming a rarer cause of death for vHL patients, although most 
deaths are still vHL-related. 
Figure 4: Manifestation rates as a function of age: A) cerebellar 
and B) retinal hbs 
A: Rate of new cerebellar hbs 
 
 
B: Rate of new retinal hbs 
 
Figure 1 from paper I. Full-drawn line: The number of new mani-
festations diagnosed per year as a function of age. 
Dotted line: 95% Confidence interval. Poisson regression was used 
to calculate age-dependent manifestation rates in pre-defined 
five-year age intervals. A restricted cubic spline function was used 
to depict the rates in smooth graphs. Subjects were included with 
delayed entry from the time of their first (A) MRI or CT of the CNS 
or (B) ophthalmoscopy. A is based on 120 cerebellar hbs. B is 
based on 88 retinal hbs. 
 
We analyzed the survival and causes of death of 143 VHL muta-
tion-carriers (67 deceased and 76 living). The VHL mutation-carri-
ers born after 1955 had a significantly better survival compared to 
earlier vHL birth cohorts. Consistently, the Cox-regression model 
demonstrated that birth years had a significant effect on vHL sur-
vival; the later a patient was born, the better the survival. The 
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separate effects of birth year, sex, genotype, and surveillance at-
tendance can be seen in Table 7. 
Survival was significantly poorer for female VHL mutation-carriers 
compared to their male counterparts, as the female hazard of 
vHL-related death was more than twice as high (Table 7). The ef-
fect of being male or female significantly depended on the pa-
tient’s genotype, with the lowest mortality rates for male mis-
sense mutation-carriers, whose hazard of vHL-related death was 
almost 5 times lower than for female missense mutation-carriers 
(p<0.001). 
Overall, about half the included vHL cohort (55%, 79 of 143) had 
attended regular surveillance at some point in their life (median 
number of years with surveillance: 12 years, range: 1- 35 years). 
We only found a significant effect of surveillance if we took the 
patient’s genotype in account. 
Table 7: Effect of birth year, sex, and genotype on overall mor-
tality and on vHL-related mortality rates 
Covariate 
Overall mortality rate vHL-related mortality rate 
HR 95% CI 
p-
value 
HR 95% CI 
p-
value 
Birth year 0.98 
0.96 -
1.00 
0.036 0.98 
0.96 – 
1.00 
0.056 
Sex  
(female vs. 
male) 
2.25 
1.16 – 
4.35 
0.016 2.25 
1.20 – 
4.20 
0.011 
Genotype 
(missense 
vs. truncat-
ing muta-
tion) 
0.58 
0.24 – 
1.40 
0.224 0.54 
0.24 – 
1.24 
0.145 
Surveil-
lance at-
tendance 
(yes vs. no) 
0.54 
0.13 – 
2.23 
0.394 0.52 
0.134 – 
2.05 
0.352 
Table 4 from Paper III.  
95% CI: 95% Confidence Interval. HR= Hazard ratio 
Included in the analysis are 132 vHL patients born after 1900 (70 
women and 62 men; 62 VHL missense mutation-carriers and 70 
carriers of VHL truncating mutations). 
The separate effects of birth year, sex, genotype, and surveillance 
attendance on the hazards of death form any cause and death 
from a vHL-related cause. In this Cox regression model the four co-
variates are all included in the same model. In this model, we did 
not include interaction terms.  
 
Truncating mutation-carriers, who overall had the poorest sur-
vival, had the largest benefit from surveillance. Their risk of vHL-
related death was significantly lower for those who had attended 
surveillance compared to those who had not (HR=0.22, 95% CI: 
0.07-0.69, p= 0.0095).  
 
Overall, the majority of all deaths among vHL patients are directly 
or indirectly related to vHL (79%, 53 of 67 deaths), Figure 5. 
The pattern of vHL-related causes of death has changed over 
time. From RCC and CNS hb being equally frequent causes of 
death among the older generations born between 1900-1955 
(42% of deaths related to RCC and 42% to CNS hbs) to almost all 
causes of death being related to CNS hbs in later years (83%, 5 of 
6 deaths among patients born after 1955) 
Figure 5: Causes of death among vHL patients (N= 67 deaths) 
10
4
27
19
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0
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vHL-related causes
 
 
When compared to their 137 siblings without vHL, the VHL-muta-
tion-carriers had a poorer survival, especially female patients who 
had a mortality rate that was eight times as high as their female 
siblings (HR=8.09, 95% CI: 4.88-13.4, p< 0.001). Comparably, the 
mortality rates of the male patients were about twice as high 
(HR=2.25, 95% CI: 1.02-4.96, p= 0.045). The same tendency was 
seen when vHL patients were compared to the general Danish 
population. The gap in the mean life expectancies of a female VHL 
mutation-carrier and a woman in the general population born in 
2000 was more than twice as large as for males (22 years vs. 10 
years). Nevertheless, the vHL life expectancy has moved much 
closer to that of the general population (Figure 6). 
 
Figure 6: Development of mean remaining lifetime for 10-year-
old individuals over time 
 
Supplementary figure 1 from Paper III. The analysis based on data 
from 74 female and 69 male vHL patients, as well as sex and age-
specific death rates for Danish birth cohorts from 1900 to 2014. 
For example a male VHL-mutation-carrier, who is 10 years old in 
2010 (born in 2000) has an estimated mean remaining lifetime of 
57.3 years (mean total lifetime of 67.3 years); that corresponds to 
10.1 years less than the estimated mean remaining lifetime of a 
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boy in the general population born in the same years (Mean re-
maining lifetime in 2010: 67.5 years/ total mean lifetime 77.5 
years). 
Paper IV: Penetrance, prevalence, and incidence of vHL 
The penetrance of vHL was found to be up to 87% at age 60 based 
on the clinical information of 150 already diagnosed vHL patients. 
The overall penetrance, which also included manifestations diag-
nosed due to surveillance, was higher than the incidence of symp-
tomatic manifestations at all ages (Table 8). The penetrance of 
symptomatic manifestations gives an estimate of the natural his-
tory of the vHL phenotype, if vHL patients did not attend surveil-
lance. 
vHL seems to be underdiagnosed in Denmark. We found 122 diag-
nosed vHL patients who had been alive at some point during the 
study period using the vHL Research Database. Through the 
search of the national health registers, we identified an additional 
71 individuals who fulfilled the Danish clinical diagnostic criteria 
during the same period (69 by having at least two registered vHL-
related manifestations, and two by having one manifestation and 
a first degree-relative with two manifestations) (assumed vHL pa-
tients). They were identified through evaluation of the full regis-
tered medical histories of 335 possible vHL patients (based on se-
lected diagnostic ICD-codes) and 205 first-degree relatives. 
 
Table 8: vHL penetrance 
 A B 
 Penetrance of vHL (re-
gardless of mode of diag-
nosis)  
(95% CI) 
Penetrance of sympto-
matic vHL 
(95% CI) 
10 
years 
0.07 
(0.02 - 0.11) 
0.03 
(0.001-0.06) 
20 
years 
0.30 
(0.23 -0.38) 
0.16 
(0.10-0.23) 
30 
years 
0.57 
(0.48-0.64) 
0.44 
(0.34-0.52) 
40 
years 
0.78  
(0.70-0.84) 
0.66 
(0.56-0.75) 
50 
years 
0.86 
(0.79 -0.91) 
0.78 
(0.68-0.85) 
60 
years 
0.87  
(0.80-0.92) 
0.80 
(0.69-0.86) 
Based on Figure 2 and Table 2 in Paper IV. N= 150. In A; all first 
manifestations are considered as events regardless of whether the 
manifestation was symptomatic or asymptomatic at diagnosis, 
subjects are censored at age of death or study end if no first mani-
festation has been diagnosed. In B; only symptomatic first mani-
festations are considered as events, while first manifestations that 
were asymptomatic at diagnosis were censored at the age at di-
agnosis. 
 
We estimate the vHL point prevalence and birth incidence esti-
mates (Table 9) based on both the international clinical diagnostic 
criteria (requiring that at least one manifestation must be a hb) as 
well as using the Danish clinical diagnostic criteria [96]. 
The clinical characteristics of the 68 assumed vHL patients and 
the 84 diagnosed patients with at least two manifestations were 
compared (Table 10).  
Table 9: Point prevalence and birth incidence of vHL 
Number of  
individuals 
alive  
1st January 
2014 
Point  
prevalence 
Number of  
individuals born  
between  
1945-1964 
Birth  
incidence 
Estimate using international criteria 
91 (diagnosed 
vHL pt) +  
29 (assumed 
vHL pt with at 
least 1 hb ad-
justed for 17% 
missing) = 120 
1:46,894 
individuals 
39 (diagnosed vHL 
pt) +  
20 (assumed vHL 
pt with at least 1 
hb adjusted for 
17% missing) = 59 
1:27,271  
live births 
Estimate using Danish criteria 
91 (diagnosed 
vHL pt)  +  
52 (assumed 
vHLpt adjusted 
for 17% miss-
ing) = 143 
1:39,351 
individuals 
39 (diagnosed vHL 
pt) +  
32 (assumed vH pt 
adjusted for 17% 
missing) = 71 
1: 22,661  
live births 
Modified from table 4 from Paper IV. Pt= Patients, Hb= Hemangio-
blastoma. 
The size of the Danish population was 5,627,235 on the 1st of Jan-
uary 2014 (Statistics Denmark [134]). The number of live births 
from 1945-1964 was 1,608,966 (Statistics Denmark [134]). 
The estimates of assumed patients were then adjusted by 17% as 
a measure of missed patients in the search. 
Table 10: Comparison of the assumed and the diagnosed vHL pa-
tients with at least 2 vHL-related manifestations 
 
Assumed vHL pt 
with at least 2  
manifestations 
(N=69) 
Diagnosed vHL pts 
with at least 2  
manifestations 
(N=84) 
Frequency of pt with  
familial/non-familial 
vHL  
(based on family 
 history at diagnosis) 
Familial: 12%  
(8 of 69) 
Non-familial: 88% 
(61 of 69) 
Familial: 89%  
(75 of 84) 
Non-familial: 11% 
(9 of 84) 
Median age at first 
manifestation  
diagnosis (Range) 
50 years  
(12 – 85 years) 
23 years  
(6 -73 years) 
Frequency of pt with 
at least 1 hb (CNS or 
retinal) at the time of 
their second mani-
festation diagnosis 
67% 
 (46 of 69) 
87%  
(73 of 84) 
Frequency of pt only 
visceral lesions 
(pheo, paragangli-
oma, pancreatic le-
sions, RCC) at the 
time of their  
second manifesta-
tion diagnosis 
33% 
 (23 of 69) 
13%  
(11 of 84) 
Modified from Table 1 from Paper IV. Pt= Patient, Hb= Hemangio-
blastoma, RCC= Renal Cell Carcinoma, Pheo= Pheochromocy-
toma/Paraganglioma 
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DISCUSSION 
We primarily wanted to increase the understanding of why the 
vHL phenotype varies so much between vHL families and even 
members of the same family. Furthermore, we wanted to estab-
lish how often the vHL diagnosis may be missed in Denmark as 
well as to evaluate vHL penetrance based on a national cohort. 
 
Key findings: 
• Risk of new vHL manifestations varies with 
age, genotype, and tumor location. 
• Men tend to have higher manifestation rates 
in adulthood compared to women. 
• Pregnancy is associated with a lower fre-
quency of new manifestations. 
• vHL survival has improved significantly over 
time, and seems to be influenced by a pa-
tient’s birth year, sex, genotype, and surveil-
lance attendance. 
• vHL has been underdiagnosed in Denmark; we 
estimate the prevalence to be about 1 in 
46,900 individuals and the birth incidence to 
be about 1 in 27,300 live births. 
• We found a penetrance at age 60 of 87%, and 
only 80% among patients who have not at-
tended surveillance prior to diagnosis, accord-
ingly vHL does not exhibit full penetrance as 
previously reported. 
Which factors influence the phenotypic variability of vHL? 
Previous studies of variation in vHL manifestation development 
have focused either on the patients’ mean ages at first manifesta-
tion, total or cumulative manifestation incidence, or on the 
growth rates of individual tumors [7, 35-37, 40, 44, 45, 47, 59, 70, 
136-138]. We have demonstrated how the risk of new vHL mani-
festations is not constant, but varies over the course of a vHL pa-
tient’s lifetime. 
The impact of genotype 
Genotype significantly modulates a vHL patient’s risk of specific 
manifestation types throughout life. Generally, VHL mutations 
that lead to an absent or truncated protein product are associ-
ated with the most severe phenotypes. We found that truncating 
mutation-carriers’ risk of new manifestations was almost twice as 
high as for missense mutation-carriers. The two genotype groups 
have similar patterns of new manifestation development until the 
patients’ twenties, when the rate of new manifestations increases 
more for truncating mutation-carriers, especially due to a signifi-
cantly higher rate of new cerebellar hbs. In contrast, missense 
mutation-carriers have an overall higher rate of new retinal hbs, 
especially from 10-20 years of age. In line with our results, others 
have found truncating mutation-carriers to have a significantly 
higher risk of developing multiple CNS hbs and associated cysts 
compared to missense mutation-carriers [44, 62, 71, 139]. The as-
sociation of truncating mutations with a lower risk of retinal hbs 
is in accordance with other studies [40, 59, 109-112]. The associa-
tion is however not entirely due to concurrent loss of BRK1 along 
with VHL deletions [109-112], as only one family of three patients 
had a deleted BRK1 in our study. This points to other contributing 
mechanisms being behind this correlation or perhaps tissue-spe-
cific effects of different mutation types. 
Consistent with our study, Maher et al. found vHL survival to be 
similar for the two genotype groups when no other factors are 
considered [107]. Nevertheless, our interaction analysis revealed 
that the genotype actually has a considerable effect on vHL sur-
vival, as the effects of sex and surveillance depend significantly on 
the patient’s germline mutation. Male missense mutation-carriers 
had a substantially better survival than their female counterparts 
did. This was not true for patients with truncating mutations. 
Consistent with their more severe phenotype, truncating muta-
tion-carriers had the greatest benefit of surveillance attendance 
in relation to vHL survival. 
Correlations between germline VHL mutations and the resulting 
phenotype depend on the ability of the mutant pVHL to downreg-
ulate HIF-pathway activity [13]. Accordingly, phenotypes with 
high risk of CNS hb and RCC (type 1 and type 2B) are associated 
with VHL mutations that lead to either an absent or truncated 
pVHL that can no longer regulate the HIF pathway [140]. Mis-
sense mutations responsible for a type 2A phenotype (high CNS 
hb, but low RCC risk) result in a pVHL that is able to impair HIF-
mechanisms to some extent [140]. Type 2C (pheo only) associated 
protein products have normal abilities to suppress the HIF path-
way, but have instead lost their ability to regulate fibronectin ma-
trix assembly [140, 141]. A multitude of HIF-independent pVHL 
functions are still being discovered. Most functions are undoubt-
edly also affected differently by specific mutation types, which 
contributes further to the complex modulation of the vHL pheno-
type. 
Influence of pregnancy and sex 
Pregnancy was associated with lower rates of new tumour devel-
opment in our study. This protective effect may be long-term, as 
the rates were significantly lower up to five years after concep-
tion compared to when the patients were not pregnant. In line 
with our results, a prospective study by Ye et al. found no signifi-
cant differences in the rates of new CNS hbs or in the growth of 
existing lesions in pregnant and non-pregnant-intervals (N= 9 
women, 13 pregnancies), not even when compared to a control 
group without pregnancies (N=27)[142]. Contrary, a retrospective 
study by Frantzen et al. found that pregnancy induced cerebellar 
hbs growth (N= 12 pregnancies), but had no effect on other mani-
festation types, including hbs in other CNS locations, although the 
manifestation numbers were small [143]. The observation periods 
in both previous studies were short (mean 18.7 and 18.4 months 
after delivery, respectively) and any possible long-term effects 
may have been missed. Also, the studies did not take the 
women’s ages into account. This may have provided a bias, as we 
have now shown that manifestation rates increase in patients’ 
twenties and thirties. In our analysis, the tumor risk in pregnancy 
was compared with age-matched non-pregnant periods in the 
same female cohort. We further took the women’s genotypes and 
manifestation burdens at age 20 into account to avoid bias in 
comparing women with different basis for choosing to have chil-
dren. However, 46% of pregnancies (14 of 30) occurred before 
the women initiated surveillance, and were likely not aware of 
their tumor risk. The same was true for almost 60% (17 of 29) of 
women in the study by Frantzen et al., while all women in Ye et 
al’s study attended vHL surveillance at the time of their pregnan-
cies [142, 143]. Previous vigilance of adverse pregnancy-induced 
tumor progression may be due to the concurrence of fertile peri-
ods with symptomatic first vHL presentations in women with un-
diagnosed vHL, giving rise to biased reports. 
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Only a few studies have included sex as a variable in their anal-
yses of vHL disease progression and survival [44, 45, 49, 138, 
144]. Two studies found male and female patients’ risk of new 
retinal and CNS hbs to be similar [45, 49], and another found no 
differences in men and women’s tumor burdens [138]. We, on 
the other hand, found a tendency for men to have a more severe 
phenotype than women. The two sexes had similar risks of new 
vHL manifestations until their mid-twenties, when the male rate 
tended to increase compared to the female rate. This underlines 
that the decreased tumor risk found during and after pregnancy is 
not due to a concurrence of a naturally milder tumor develop-
ment in women in the years when they have their children com-
pared to their non-fertile ages. Male patients had a slightly in-
creased risk of CNS hb, but a lower retinal hb risk, although this 
was not significant. A recent prospective study of CNS hbs found 
that male vHL patients overall had significantly more CNS hbs as 
well as a significantly faster tumor growth compared to women 
[44]. 
Paradoxically, we found that vHL survival seemed to be signifi-
cantly poorer for women than for men despite the apparently 
more severe male phenotype. This was especially evident for mis-
sense mutation-carriers, where women had a mortality rate that 
was almost five-time as high as for men. Another smaller study 
likewise found a tendency for a poorer female life expectancy, 
but this was not significant [144]. These sex differences may be 
due to hormonal factors although this has not been investigated. 
In any case, sex differences in tumor development, tumor growth 
and possibly differences in vHL-related morbidity between men 
and women need to be further investigated. 
Other influencing factors 
As expected, we found that the rate of new manifestation devel-
opment varies with age. This is in line with other demonstrations 
of age-related risks of specific manifestation types [35, 36, 40, 49, 
59, 66]. In contrast to displaying cumulative manifestation risks or 
age-stratified prevalence [35, 36, 40, 49, 59, 66], we showed that 
the rate of new tumor development varies at different ages 
throughout life in the same vHL cohort. The risk of new manifes-
tations does not increase steadily with age, but varies in distinct 
patterns according to the location of the manifestation. Consist-
ently, biallelic VHL inactivation may be established as early as dur-
ing embryogenesis as multiple tumor precursors, which can later 
be activated to grow by yet unknown factors [18, 145]. The vary-
ing patterns of two-phased growth for individual tumors as well 
as parallel and asymmetric growth of separate tumors in different 
organs or CNS locations that are described in paper I and reported 
in [44, 45, 47, 138, 139, 146], make local tissue-specific activating 
factors such as micro environmental stimuli likely. The patient’s 
germline mutation may have different tissue-specific effects ac-
cording to the mutational consequence, as missense mutations 
have a higher risk of hbs in the retina but a lower in the cerebel-
lum, while truncating mutation-carriers have the opposite risk 
pattern.  
Initiation of tumor development is in all likelihood a complex pro-
cess requiring multiple factors. Other activating factors could be 
circulating endocrine stimuli, additional random genetic altera-
tions including epigenetic changes, or external environmental fac-
tors [47, 145, 147]. External risk-modifying factors could possibly 
be physical activity, obesity, or smoking, although this has not 
been systematically studied. A recent animal study demonstrated 
that exercise is associated with decreased tumor burden and 
growth in a mouse melanoma model through up-regulation of im-
mune responses [148]. Smoking and obesity are known risk fac-
tors for sporadic RCC development [149]. Although, curiously, in 
sporadic RCC tumors, smoking is associated with a lower fre-
quency of somatic VHL inactivation [150]. 
There are wide phenotypic variations even between family mem-
bers with the same VHL mutation suggesting additional non-allelic 
inherited genetic modifiers [49]. Variants in the gene for the Cy-
clin D1 protein, which is involved in cell cycle control, has been 
suggested to modulate the risk of hb development in vHL pa-
tients, although the association has only been demonstrated in a 
single study [151].  
Also, the type of second hit, i.e. the somatic inactivation of the 
wildtype VHL allele (point mutation, deletion, epigenetic inactiva-
tion etc.) as well as additional somatic genetic alterations will 
contribute to the cellular phenotype of the individual precursor 
lesions. Recent studies using next generation sequencing (NGS) of 
multiple tumors from individual vHL patients have shown that dis-
tinct somatic genetic changes have occurred in the individual tu-
mors [152, 153]. The tumors from the same individual do how-
ever also share similar patterns of somatic variation, suggesting 
that both tumor-specific as well as individual factors, either ge-
netic modifiers in the germline or environmental factors, are im-
portant for tumor development [152, 153]. The sequence of vHL-
related tumorigenesis is still not fully understood, which limits our 
ability to truly predict vHL tumor progression. 
Implications for genetic counseling and surveillance 
Our estimates of how frequently new vHL manifestations are di-
agnosed in a given age-interval can help clinicians to assess a vHL 
patient’s probability of manifestation development at specific 
ages. This is useful in a genetic counseling setting, and could form 
the basis of future targeted surveillance strategies that better en-
sure efficient surveillance for the individual patient that both min-
imizes the risk of missing potential life-threating new manifesta-
tions, while also keeping the psychological strain at a minimum. 
Pre-symptomatic diagnosis of retinal hbs is especially important, 
as vision loss can be prevented by early treatment in most cases 
[39]. The risk of vision loss is reported to be significantly lower 
when diagnosed pre-symptomatically versus symptomatically (p < 
0.001, cumulative risks of vision deficits by 40 years: 35% versus 
82%, respectively) [39]. Retinal hbs are most frequent in patients’ 
teenage years and early twenties, and regular ophthalmological 
surveillance is especially important in this period of their lives. Af-
ter about 30 years of age the rate of new retinal tumors is persis-
tently low corresponding to only about one new tumor every 
tenth year. In line with this, a large study of retinal hbs found that 
the risk of permanent vision loss due to retinal tumors was high-
est before the age of 30 [39]. We believe that retinal surveillance 
could be relaxed in older individuals with longer intervals be-
tween examinations, especially for truncating mutation carriers 
who have an overall lower risk of retinal hbs. Particular focus on 
screening for CNS hbs is advised from vHL patients’ thirties where 
manifestation rates peak, mainly for truncating mutation-carriers. 
As CNS hbs are the major cause of vHL-related death and respon-
sible for most long-term sequelae [138], an early diagnosis is es-
sential to give the surgeons the most optimal conditions for plan-
ning the appropriate treatment approach [48]. 
Based on our results, pregnancy should not be discouraged for fe-
male vHL patients based on their predisposition alone, and we do 
not recommend intensified surveillance of pregnant vHL patients, 
which contrasts recommendations of previous studies [117, 143]. 
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If women have already diagnosed manifestations, appropriate 
specialist evaluations of risk of growth or complications due to 
pregnancy might occur, and any additional measure can be taken 
based on the individual situation. 
The frequency of RCC-related deaths has decreased over time. 
This can most likely be attributed to surveillance-facilitated early 
RCC diagnosis. Ong et al. compared a British vHL cohort (N=573) 
of which 20% had been diagnosed with vHL pre-symptomatically, 
and who had attended surveillance to the clinical characteristic of 
part of the same cohort diagnosed due to clinical vHL (N=152) 
when they had just initiated surveillance 17 years earlier [35, 36]. 
They found that the frequency of RCC diagnosis had increased in 
patients who had attended surveillance (35% vs. 28%). Further-
more, the RCCs were diagnosed at a significantly younger age in 
the surveillance group (39.7 vs. 44 years, p= 0.026) [36], suggest-
ing diagnosis at earlier tumor stages. 
 
We did not find any significant effects of surveillance attendance 
on vHL survival, when genotype was not considered. This could in 
part be due to the late start of surveillance for many patients 
(median age of surveillance initiation: 24 years, range: 0-67 
years). Also, our strict definition of regular surveillance attend-
ance may underestimate the true extent of surveillance, and our 
material may be too small to see any significant effect. Before of-
ficial guidelines were published [154], many vHL families did at-
tend pre-symptomatic screening, but not always in regular inter-
vals. Many of these periods are not counted as surveillance 
attendance, which may underestimate the true effect of surveil-
lance. In fact, we have previously found a surprisingly high com-
pliance to surveillance in part of this cohort  as far back as in the 
early 1990’s [37], which contrasts other reports of low surveil-
lance compliance among vHL patients [53, 132, 155]. 
 
A very important purpose of surveillance is to minimize vHL-re-
lated morbidity, especially long-term sequelae such as blindness, 
neurological deficits, loss of kidney function, thereby improving 
the patients’ quality of life. We did not account for these factors 
in the present study, and the impact of surveillance on vHL-re-
lated morbidity has yet not been directly assessed. A recent pro-
spective Italian study evaluated vHL-related disabilities among pa-
tients who had attended surveillance, but had no control group. 
They found a high rate of patients with neurological impairments, 
however, despite this the majority of patients had only minor ef-
fects on their ability to carry out normal daily activities [138]. 
Even though some patients in this study were followed for up to 
16 years, the median follow-up time was 45 months, suggesting 
that many patients may not have attended long-term surveillance 
[138]. The effects of surveillance are expected to be even more 
evident in pre-symptomatically diagnosed VHL mutation-carriers 
who have attended surveillance from early childhood. 
In the future, as antiangiogenic drugs or other systemic treat-
ments may be available for pre-symptomatic treatment of espe-
cially CNS tumors, the benefit of very early manifestation diagno-
sis through surveillance can become even more important [124]. 
Challenges in vHL diagnosis 
vHL is not always acknowledged on account of its rarity as well as 
involvement of numerous clinical specialties. Many vHL patients 
may not be diagnosed at the most optimal time, which is essential 
for establishment of surveillance and the offer of genetic counsel-
ing. We demonstrate that vHL has been underdiagnosed in Den-
mark. Many individuals in whom the diagnosis is delayed or 
missed entirely may be asymptomatic or very mildly affected VHL 
mutation-carriers, even late in life. vHL does not seem to be as 
highly penetrant as previously reported, and as many as 20% of 
VHL mutation-carriers may still be asymptomatic and undiag-
nosed at age 60, if they have never attended surveillance. 
vHL prevalence and incidence in Denmark 
When including both diagnosed and yet undiagnosed assumed 
vHL patients, we found high estimates of vHL prevalence (1 in 
about 46,900 individuals) and birth incidence (1: 27,300 live 
births) compared to most previous studies [7-10]. Our estimates 
are even higher, if we use the Danish diagnostic criteria, as they 
also include individuals without a hb, but with two other vHL-re-
lated manifestations. The estimates based on Danish criteria are 
however not directly comparable to previous estimates based on 
international diagnostic criteria. Also, our register search for as-
sumed vHL patients is more complete according to international 
criteria, as we were able to find individuals with multiple hbs, but 
not those with multiple manifestations of most other types. Previ-
ous prevalence and incidence estimates vary widely, from 1 in 
39,000 to 1 in 91,000 individuals and the birth incidence from 1 in 
36,000 and 1 in 53,000 live births in different populations [7-10]. 
All were based on selected patient cohorts and have been re-
gional estimates, that may be influenced by random genetic drift 
and founder effects [9]. Further, most previous estimates were 
based on cohorts of clinically affected patients, which would un-
derestimate the number of VHL mutation-carriers [7-10]. Our esti-
mates are based on a national cohort that includes all vHL pa-
tients with a genetic diagnosis as well as those clinically affected. 
The increase in the Danish prevalence of diagnosed vHL patients 
from 67 living patients in 2008 to 91 living patients in 2014 can in 
part be attributed to improved vHL diagnosis and survival. Also, 
many VHL mutation-carriers are in their reproductive age, and 
nine of their children born after 2008 were pre-symptomatically 
diagnosed as VHL mutation-carriers. In recent years, the national 
Danish vHL coordination group (see Appendix 1) has been formal-
ized, and has gained many new specialists, which enables a strong 
multi-disciplinary effort and strengthened awareness about vHL 
among medical professionals throughout the country. 
vHL penetrance 
We found that vHL penetrance was 87% at age 60, and if we only 
considered patients who had not attended surveillance prior to 
their first manifestation diagnosis, only 80% would have had 
symptoms at this age. This is much lower than previous estimates, 
where vHL penetrance has been reported to be almost 100% at 
60 years [7, 8]. Previous estimates were based on cohorts of clini-
cally affected patients diagnosed before accurate genetic testing 
was available. This could have biased the estimates towards the 
more severe phenotypes, as asymptomatic or mildly affected VHL 
mutation-carriers were not included. In our study 14% (15 of 106) 
of the cohort were asymptomatic mutation-carriers, while only 
3.6% (3 of 83) and less than 0.5% (1 of 236), respectively, were 
asymptomatic obligate mutation-carriers included in the previous 
cohorts [7, 8]. Since genetic testing has become the main diagnos-
tic tool for vHL, several cases of asymptomatic mutation-carriers 
older than 60 years have been reported [39, 133, 156]. In our co-
hort, 16 mutations-carriers had lived to be more than 60 years old 
without any symptoms of vHL. 
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Implications for vHL diagnosis and genetic counseling 
The notion that vHL is fully penetrant at age 60 years has proba-
bly influenced the diagnostic approach to vHL families. In the 
Danish families with a known pathogenic VHL mutation, a surpris-
ingly high number of the living first-degree relatives (39%, 55 of 
141) have never been genetically tested (median age: 62 years, 
range: 1 – 99 years). The finding of a lower penetrance than previ-
ously assumed could have important consequences for genetic 
counseling of adult asymptomatic first-degree relatives and pa-
tients with late-onset vHL-related tumors.  
The lower penetrance seen in our study could also have implica-
tions for assessment of vHL as a possible differential diagnosis. 
Based on the observed lower penetrance, many VHL mutation-
carriers may have milder phenotypes with only a single vHL-re-
lated manifestation and perhaps no family history of vHL. Up to 
11% of patients with an apparently isolated pheo with no family 
history and no other vHL related symptoms, have a germline VHL 
mutation [34, 77, 83]. The same goes for up to and 18% of solitary 
CNS hb patients, respectively [41, 70, 71, 157]. Several groups 
recommend that all patients with a single retinal or CNS hb, a sin-
gle pheo, or a single early-onset RCC (< 50 years) should be genet-
ically tested for VHL mutations [96, 119, 156]. 
Through the national Danish health registers, we identified 71 in-
dividuals who we assessed to fulfill the Danish clinical diagnostic 
criteria based on their registered diagnostic ICD-codes (assumed 
vHL patients). According to the national vHL Research Database 
they had not been diagnosed with vHL. The majority of the as-
sumed vHL patients were non-familial cases, which contrasts the 
high proportion of familial cases usually found among the diag-
nosed patients [7, 62, 158, 159],paper IV. On one hand, non-fa-
milial cases are more easily overlooked, and we would expect 
most undiagnosed VHL mutation-carriers to be de novo cases. On 
the other hand, previous estimates of de novo mutations are 
much lower, between 3 and 21% [6, 62, 64, 158]. Based on our 
finding that vHL is not fully penetrant, previous reported de novo 
mutation cases might in reality be cases of non-penetrance in an 
asymptomatic parent with a germline VHL mutation, who has not 
been genetically tested. We assessed that 22 patients had de 
novo mutations based on their family histories in paper IV, but 
this had only been genetically confirmed in one family. Apparent 
de novo cases could also be due to mosaicism in a parent, though 
this is reported in only up to 5% [159]. 
Some of the identified assumed vHL patients may have a different 
diagnosis. About a third of the assumed patients (20 of 69) had 
only visceral lesions and would not have fulfilled the international 
diagnostic criteria [4]. The majority (60%, 12 of 20) had a combi-
nation of a RCC and a neuroendocrine tumor (a pheo, a paragan-
glioma, or a PNET). Some may be phenocopies, while others may 
have vHL type 2C or another pheo predispositions such as Multi-
ple Endocrine Neoplasia 2A or SDH-associated hereditary pheo/ 
paraganglioma syndrome [160]. VHL germline mutation have 
been found in up to almost 40% of familial pheo cases, while the 
rest or caused by other genes or unknown causes [81, 161, 162]. 
Among the diagnosed vHL patients, as many as 13% (11 of 84) 
had only visceral manifestations and no hbs at the time of their 
second manifestation diagnosis, when they would have fulfilled 
the diagnostic criteria on a purely clinical basis. This underlines 
the usefulness of the more inclusive Danish diagnostic criteria 
compared to the international criteria. 
In a clinical setting, multiple aspects are taken into account be-
fore a vHL diagnosis is made, including the clinical characteristics 
of the individual and the family. Rarer phenotypic presentations, 
such as solely visceral lesions require particular attention to dif-
ferential diagnoses, and often multigene testing will be consid-
ered [96]. The greatest challenge lies in assessing whether pa-
tients with only visceral lesions, in whom no VHL mutation has 
been found and all other differential diagnoses have been ruled 
out, should attend vHL surveillance, as they would still fulfill the 
Danish diagnostic criteria. Better knowledge about the risk of ad-
ditional manifestations in such families is needed to facilitate ap-
propriate surveillance measures. 
STUDY STRENGTHS AND LIMITATIONS 
Several elements contribute to the strength of the reported re-
sults. The included papers are all based on national studies that 
identified all known VHL mutation-carriers regardless of genotype 
or phenotype, which limits the risk of selection bias. Further, due 
to the free and equal health care system in Denmark, any bias 
caused by socio-economic disparities in surveillance or treatment 
options is negligible. 
The results are based on a comprehensive, reliable, and well-doc-
umented data set that accounts for the entire lifetime of each of 
the included individuals. Almost all (98%, 1,182 of 1,209) of the 
diagnosed manifestations were documented through hospital rec-
ords or register data. The approach of using a longitudinal per-
spective in which we included the patients’ entire life spans ena-
bles us to demonstrate changes over several decades, both for 
the individual vHL patient, but also for the entire cohort. 
Certain study limitations should, nevertheless, be taken into ac-
count: 
Study design 
• The included papers are all based on retrospective stud-
ies, as this approach allowed us to include long follow-
up time for each individual. 
Risk of selection bias 
• As the study cohort has been selected based on a spe-
cific diagnosis, any yet undiagnosed families are not in-
cluded. The possible vHL probands identified in paper IV 
were for example not included in the previous papers’ 
analyses. Although most were seemingly de novo cases, 
the extent of any asymptomatic mutation-carriers in 
their families is unknown. Also, a large number (39%, 55 
of 141) of currently living first-degree relatives in known 
vHL families have not been genetically tested. Although 
apparently asymptomatic, some may be mutation-carri-
ers. 
• In papers I, II, and III we solely included confirmed VHL 
mutation-carriers, as the underlying genetic cause of 
the vHL phenotype or the natural history of the disease 
is unknown in families without identifiable VHL muta-
tions. The group of vHL patients who fulfill the clinical 
diagnostic criteria without identifiable VHL mutations is, 
however, very small, and any differences would have 
minimal influence on the overall estimates. 
• In the clinical characteristics analysis in paper IV, not all 
known vHL patients were included. Nevertheless, when 
we compared the 16% (15 of 91) who were not included 
to the 150 included patients, their characteristics were 
similar, except for an overweight of asymptomatic VHL 
mutation-carriers in the non-included group compared 
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to the included group (40%, 6 of 15 vs. 13%, 20 of 150). 
(Appendix 3).  
Limitation of use of national health registers 
In paper IV, we searched directly for undiagnosed individuals who 
could fulfill the clinical diagnostic vHL criteria (assumed vHL pa-
tients). Nevertheless, our search strategy probably underesti-
mated the frequency of assumed vHL patients. 
• For every contact with the health care system, the 
treating hospital department/physician is responsible to 
code the procedures performed and the diagnoses sus-
pected/given during the contact and to report these 
codes to the relevant registers. Therefore, different 
doctors may not use the diagnostic codes uniformly to 
code the same manifestation types. The variation is 
largest for manifestations that do not have their own 
specific ICD-code, such as retinal hb. Even though spe-
cific codes are available for hbs of the cerebellum, they 
are still often coded using ICD-codes for benign or ma-
lignant supratentorial tumors or tumors in unspecified 
locations (see Supplementary report about the pilot 
study in Paper IV for details). Nevertheless, as we in-
cluded all hbs based on their morphological code, re-
gardless of location-specific ICD-codes, which would 
identify all hbs that have been surgically removed. 
Since 2000, the government funding of hospital depart-
ments/private practitioners depends on a system in 
which the codes used for diagnoses and procedures 
lead to different payment rates, which may have biased 
the use of certain codes over others [163]. 
To our knowledge, the ICD-codes used in our register 
search have not been validated on a larger scale to en-
sure that the specific codes are used for the intended 
underlying conditions that we wish to find. This has 
been done for a variety of other conditions (stroke, cho-
lesteatoma, and venous thromboembolisms) with posi-
tive predictive values of the ICD-codes registered in the 
Patient Register of about 80-90% [164-166]. We did per-
form a pilot study to choose the codes to be used in the 
search. In the pilot study, the hospital records of diag-
nosed vHL patients (N=37) were compared to their diag-
nostic codes. 
• In paper IV we used only the Patient Registry combined 
with the Cancer registry in our initial search. We subse-
quently used the Pathology Register for diagnosis con-
firmation, and discovered that this register had a more 
accurate and complete registration of vHL-related mani-
festations diagnosed among the known vHL patients. In-
clusion of the Pathology Register in our initial search 
would have yielded a more accurate search result. 
• In the register search in paper IV, we were only able to 
evaluate the full medical records for individuals who 
were alive in 1968 (and received a CRS identification 
number). Assumed vHL patients who were born in the 
time period used to calculate birth incidence (1945-
1964), but wo had died before 1968 or who had mani-
festations diagnosed before the start of the study pe-
riod (1977) from when we had register data, would not 
have been found. 
•  In paper IV we did not obtain register data for 38% (126 
of 331) of the identified first-degree relatives to the as-
sumed vHL patients. This may have underestimated the 
frequency of familial cases among the assumed vHL pa-
tients. We do, however, not asses this bias to be very 
large, as any first-degree relatives with a retinal or CNS 
hb or two different vHL-related manifestations would 
have been identified in our initial search. Among the 
126 evaluated first-degree relatives, we found about 3% 
(6 of 205) to be affected. From this, we can extrapolate 
that up to four affected first-degree relatives (3% of 
126) may have been missed among the non-evaluated 
first-degree relatives. 
Genotype classification 
• In our genotype analyses in paper I and III, we focused 
on two broad genotype categories (missense and trun-
cating VHL mutations). VHL genotype-phenotype corre-
lations have been categorized in further detail, both ac-
cording to the mutation type, its intragenic location, 
relation to functional domains, and structural integrity 
of pVHL [36, 108, 167, 168]. Due to the limited number 
of Danish vHL families, we were not able to account for 
the genotype effects in greater detail. 
• The Danish distribution of missense and truncating mu-
tations (44% and 56%), Appendix 3 seems to be slightly 
skewed compared to distributions reported internation-
ally, where between about 50-65% of all identified 
germline VHL mutations are missense mutations [6, 16].  
As families with missense mutations are more likely to 
be missed than those with truncating mutation-carriers, 
owing to the often milder phenotypes of missense mu-
tation-carriers, there may have been a tendency for 
families with missense mutations to be underdiag-
nosed. The higher frequency of truncating mutation-
carriers in the Danish cohort might be because less Dan-
ish vHL families are overlooked. 
Factors not accounted for and conservative definitions 
• In papers I and II, we focused only on the development 
of new manifestations and did not take growth or asso-
ciated cyst development of any already diagnosed man-
ifestations into account. We have no evidence that the 
same factors are involved, however, hypothesize similar 
growth mechanisms for initial growth of microscopic 
precursor lesions and of larger detectable tumors, when 
their sizes increase. 
• In paper I’s analyses of retinal or cerebellar manifesta-
tion rates, any hbs diagnosed at the patients’ first ever 
brain scan or ophthalmoscopy were not included, as it 
was impossible to determine the exact age at which the 
manifestation could have been detected. We did this to 
avoid a falsely high manifestation rate at the time of 
their first examination. This approach may nevertheless 
cause a systematic bias that could generate underesti-
mated manifestation rates in the youngest age groups. 
But, when we considered all manifestation types, we in-
cluded all first manifestations and the manifestation 
rates were not markedly higher in the younger age 
groups. 
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CONCLUSION AND PERSPECTIVES 
The full complexity of vHL-related tumorigenesis is unraveling, 
and many yet unidentified factors are likely to influence tumor 
development and subsequently the patients’ phenotypes. The 
more widespread use of NGS techniques and increasing focus on 
epigenetics will facilitate identification of potential genetic modi-
fiers in the germline as well as genetic drivers of tumorigenesis, 
which could be used in phenotype predictions, or as potential 
drug targets. 
Even though we cannot yet accurately predict the specific pheno-
type of the individual patient, our results are useful when answer-
ing families’ questions about what to expect from their disease, 
as often posed in a clinical genetic setting. We document that vHL 
survival has improved, and is getting closer to the survival of indi-
viduals without vHL. This could have important implications for 
many international patients’ problems with life and health insur-
ances. Our results form the basis of improved individualized sur-
veillance recommendations. We provide evidence as to which fac-
tors influence new tumor development and vHL survival. 
Especially the finding that pregnancy is associated with decreased 
tumor development is important for female patients, who can be 
reassured that pregnancy does not increase their risk of new tu-
mors, and who do not need intensified surveillance during preg-
nancy. The finding that women have a lower life expectancy than 
men, even though men seem to have more severe phenotypes is 
surprising and needs to be further studied in other vHL cohorts. 
The concept of vHL as a very rare and highly penetrant disease 
may be changing. New genetic testing approaches has made 
multi-gene testing available. The indications for when to include 
the VHL gene in multigene analyses may become wider, the eas-
ier and more cost-effective analyses becomes. This could lead to a 
wider phenotypic spectrum with a higher frequency of mildly af-
fected VHL-mutation-carriers, giving rise to even lower pene-
trance estimates. Many at-risk family members, especially par-
ents or siblings to adult probands have not been genetically 
tested. Based on previous penetrance estimates, the probability 
of a VHL mutation-carrier having had a manifestation in their thir-
ties or forties would be around 80% and 90%, respectively. The 
risk of older first-degree relatives may in some cases have been 
perceived as negligible, if they had reached a certain age without 
symptomatic manifestations. Based on our penetrance calcula-
tions, however, the age-related penetrance is much lower, which 
greatly influences risk assessment in a clinical genetic setting. vHL 
is still not recognized as the underlying cause of disease in many 
families, who are not offered genetic counseling or surveillance. 
Even though the Danish prevalence has increased over recent 
years, vHL still seems to be underdiagnosed, and there is further 
need for increased awareness about vHL for doctors who may en-
counter the disease. 
APPENDIX 1: THE DANISH VHL COORDINATION GROUP 
As vHL management is a multidisciplinary effort, it is essential 
that surveillance is organised in collaboration between the in-
volved specialists. In Denmark, a national vHL coordination group 
has been established, which consists of medical specialists from 
all over the country covering all aspects of vHL-associated special-
ties: Clinical and molecular genetics, Ophthalmology, Neurosur-
gery, Urology, Endocrinology, Radiology, Otology, Gastroenterol-
ogy, vHL Researchers, and The Danish vHL Patient Society. 
Besides writing the national surveillance recommendations [96], 
the group has developed a mobile chart for patients to help them 
keep track of their surveillance program and the current recom-
mendations. Also, most group members function as clinical coor-
dinators for vHL patients in their region, and are in charge of 
managing the patients’ referrals to their surveillance examina-
tions. 
APPENDIX 2: DESCRIPTIONS OF THE EMPLOYED NATIONAL 
HEALTH REGISTERS 
The Civil Registration System, (CRS) [169, 170]: Contains each resi-
dent’s unique CRS number, name, vital status, dates of birth and 
death, sex, places of birth and residence, information about mi-
gration, and the CRS numbers of parents, children, and spouses. 
Individuals deceased before the initiation of the CRS in 1968 are 
not registered. A source of uncertainty is that family registrations 
are based on legal and not biological relationships, so adopted 
and biological children cannot be differentiated. Family relation-
ships are only registered for individuals born after 1950, and 
when the CRS started, parent-child relationships only if they had 
the same address. 
The Patient Register [163]:  Contains data about all somatic hospi-
tal admissions from 1977 (including all diagnoses and surgical pro-
cedures performed). From 1995, emergency room and outpatient 
contacts were also registered. Diagnoses are coded using ICD-
codes (ICD-8 from 1977-1994 and ICD-10 from 1995-present). The 
data is registered electronically by the treating doctor, who is also 
responsible for choosing the most appropriate ICD-codes for the 
contact. 
The Cancer Register [171]: Contains information about the inci-
dence of different malignancies and benign CNS tumors. The reg-
ister was initiated in 1943, but registration was not mandatory 
before 1987. ICD-7 were used before 1978, and ICD-10 codes af-
ter. Each tumor is registered separately, and morphology was reg-
istered from 1978. Registrations are received from treating hospi-
tals. Data is validated through cross-reference with the Patient 
register and the Pathology Register. 
The Pathology Register [172]: Contains information about all his-
tological specimens examined at Danish Pathology departments. 
The register was initiated with standardized national registration 
in 1997, but also includes data dating back to the 1970ies from 
some departments (the different departments have varying start 
dates, so registration cannot be considered complete before 
1997). The register is updated daily. Diagnoses are coded and re-
ported electronically by the examining pathologist using SNOMED 
(Systematized Nomenclature of Medicine)-codes. 
The Causes of Death Register [173]: Contains information about 
date of death, manner of death, and causes of death (direct and 
indirect causes as well as other conditions that may have contrib-
uted to the death) as registered on the Death Certificate from 
1970. Diagnoses have been registered with ICD-10 codes since 
1994. Until 2007, the ICD-codes were chosen by trained coders in 
the National Board of Health based on the written diagnoses on 
the death certificate filled out by a doctor. From 2007, doctors 
themselves reported the death certificate electronically and 
chose the ICD-codes. 
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APPENDIX 3: ADDITIONAL TABLES 
Characteristics of the included 150 vHL patients for whom we have specific clinical information and the 15 vHL patients who have 
declined active study participation. 
 
Included vHL patients 
(N= 150) 
Non-included vHL patients: (Total N= 15)1 
1) have decline active study participation (N= 6), 
2) not responded to our study invitation (N= 6), 
3) were not contacted (N= 3) 
Vital status and age 
74 deceased  
(median age at death: 
45 years, range: 12 – 88 years) 
 
76 living 
(median age2: 39 years,  
range: 1-73 years) 
0 deceased 
 
 
 
15 living 
(median age: 33 years, 
range: 3- 71 years) 
Genotype 
Truncating mutation-carriers 
48% 
(72 of 150) 
40% 
(6 of 15) 
Missense mutation-carriers 
44% 
(66 of 150) 
40% 
(6 of 15) 
No identifiable VHL mutation 
5% 
(8 of 150) 
20% 
(3 of 15) 
Never genetically tested 
3% 
(4 of 150) 
0 % 
(0 of 15) 
Clinical characteristics 
Frequency of individuals without 
diagnosed vHL manifestations 
13% 
(20 of 150) 
40% 
(6 of 15) 
Median age at first manifestation 
diagnosis 
26 years 
(Range: 6 – 73 years) 
21 years 
(Range: 16 -55 years) 
Manifestation types 
 
 
Incidence 
(N= Number of af-
fected subjects) 
Subjects with type as first 
manifestation 
(% of all subjects with manifes-
tations N= 130)2 
Incidence 
(N= Number of 
affected sub-
jects) 
Subjects with type as first mani-
festation 
(% of all subjects with manifesta-
tions N= )2 
Retinal hbs 
46% 
(69 of 150) 
32% 
(42 of 130) 
56% 
(5 of 9) 
33% 
(3 of 9) 
Cerebellar hbs 
61% 
(91 of 150) 
38% 
(49 of 130) 
44% 
(4 of 9) 
33% 
(3 of 9) 
Brainstem hbs 
15% 
(22 of 150) 
4% 
(5 of 130) 
22% 
(2 of 9) 
11% 
(1 of 9) 
Spinal 
Hbs 
27% 
(41 of 150) 
3% 
(4 of 130) 
44% 
(4 of 9) 
11% 
(1 of 9) 
Supratentorial hbs 
3% 
(4 of 150) 
1% 
(1 of 130) 
11% 
(1 of 9) 
11% 
(1 of 9) 
ELSTs 
2% 
(3 of 150) 
0% 
(0 of 130) 
0% 
(0 of 9) 
0% 
(0 of 9) 
RCC 
30% 
(45 of 150) 
11% 
(14 of 130) 
33% 
(3 of 9) 
0% 
(0 of 9) 
Renal cysts 
41% 
(62 of 150) 
- 
11% 
(1 of 9) 
0% 
(0 of 9) 
Unspecified renal tumors 
5% 
(8 of 150) 
8% 
(10 of 130) 
0% 
(0 of 9) 
0% 
(0 of 9) 
Pancreatic cysts 
29% 
(44 of 150) 
8% 
(10 of 130) 
0% 
(0 of 9) 
0% 
(0 of 9) 
PNETs 
2% 
(3 of 150) 
8% 
(10 of 130) 
0% 
(0 of 9) 
0% 
(0 of 9) 
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Other pancreatic tumors 
(unspecificed or adenocarci-
noma) 
9% 
(14 of 150) 
2% 
(2 of 130) 
0% 
(0 of 9) 
0% 
(0 of 9) 
Pheos 
14% 
(21 of 150) 
8% 
(10 of 130) 
11% 
(1 of 9) 
0% 
(0 of 9) 
Paragangliomas 
1% 
(2 of 150) 
0% 
(0 of 130) 
0% 
(0 of 9) 
0% 
(0 of 9) 
Epididymal cystadenomas 
 
47% 
(7 of 150) 
4% 
(5 of 130) 
0% 
(0 of 9) 
0% 
(0 of 9) 
Cysts of the broad uterine liga-
ment 
1% 
(2 of 150) 
0% 
(0 of 130) 
0% 
(0 of 9) 
0% 
(0 of 9) 
Inclusion: Here refers to active study participation: interviews, letting us use hospital records, providing a blood sample.  
Out of the 165 known living and deceased vHL patients ever known to be diagnosed with vHL in Denmark. From the vHL Research Data-
base and the current study, we have documented clinical information about 150 of them (99% (1198 of 1209) of their manifestations are 
documented by medical records, the rest (1%, 11 of 1209) only through family information). Of these 150 individuals, 40 (27%) had not 
been systematically examined for vHL manifestations or had an autopsy. Their manifestations were only diagnosed due to symptoms, 
and the number of manifestations that are unaccounted for is unknown. 
1: The 3 first-degree relative with possible vHL diagnosed in the register study in paper I are not included in this group, as their diagnosis 
has not been confirmed. Information about the 15 non-included individuals was obtained based on information from previous research 
projects and registrations in the vHL Research Database and/or health registers. The information is therefore not documented through 
hospital records and information about manifestations may be incomplete. The 15 non-included patients came from 12 families, all but 3 
families were represented in the study as other family members were included. 
2: Current age was taken as age on the 1st January 2016 
3 : If more than 1 manifestation type was diagnosed at the same time, we counted both as first manifestations. 
 
The genotypes of the diagnosed Danish vHL families with pathogenetic VHL germline mutations 
Family no. 
No. of VHL mut-carriers in the 
family 
VHL mutation (c.DNA/p.Protein) Assessed to be truncating (T) /missense (M)1 
1 22 c.278G>A (p.Gly93Asp) M 
2 2 c.407 T>C (p.Phe136Ser) M 
3 4 c.341-? - 463+?del T 
4 34 c.433C>T (p.Gln145*) T 
5 8 c.341-?_463+?del T 
6 4 c. 499C>T (p.Arg167Trp) M 
7 3 
c.319C>T (p.Arg107Cys) AND c.353T>C 
(p.Leu118Pro) 
M 
8 10 c. 194C>T (p.Ser65Leu) M 
9 3 c.337C>T (p.Arg113*) T 
10 2 c.520_521ldupAA (p.Asn174Lysfs*29) T 
11 3 c.293A>G (p.Tyr98Cys) M 
12 1 c.269A>T (p.Asn90Ile) M 
13 2 c.239G>T (p.Ser80Ile) M 
14 3 c.l-?_463+?del T 
15 1 c.194C>G (p.Ser65Trp) M 
16 1 c.341_343insGGT T 
17 2 c.481C>T (p.Arg161*) T 
18 4 c.496G>T (p.Val166Phe) M 
19 1 c.341-?_463+?del T 
20 1 c.463+1G>T T 
21 4 c.1-?_340+?del T 
22 1 c.606dupA (p.Gln203Thrfs*53) T 
23 1 c.194C>G (p.Ser65Trp) M 
24 2 c.548C>A (p.Ser183*) T 
25 1 c.464-?_642+ ?del T 
26 3 c.464-?_642+ ?del T 
27 2 c.l-?_463+?del T 
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28 2 c.341-?_463+?del T 
29 1 c.1-?_340+?del T 
30 1 c.464-?_642+ ?del T 
31 1 c.257C>T (p.Pro68Leu) M 
32 6 c.500G>A (p.Arg167Gln) M 
33 6 c.191G>C (p.Arg164Pro) M 
34 1 c.388G>A (p.Val130Ile) M 
Total 
15 families with missense mutations (44%) and 
19 families with truncating mutations (56%) 
Supplementary table 1 from paper IV. 
The reference VHL sequence used is NM_000551.3, *= stop codon  
1: Missense mutations defined as a single nucleotide substitution leading to substitution of an amino acid. Truncating mutations defined 
as mutations predicted to truncate the gene product (nonsense, frame-shift, splice-site mutations, and exon deletions) 
 
ABBREVIATIONS 
CRS Civil registration system 
CT Computed tomography 
DNA Deoxyribonucleic acid  
EGFR Epidermal growth factor receptor  
ELST Endolymphatic sac tumor 
EPO Erythropoietin 
FISH Fluorescence in situ hybridization 
GLUT-1 Glucose transporter 1 
Hb/hbs Hemangioblastoma(s) 
HR Hazard ratio 
ICD-7/8/10  International classification of disease v. 7/8/10 
MLPA Multiplex ligation-dependent probe amplifica-
tion 
MRI Magnetic resonance imaging  
N/ No Number 
NGS Next generation sequencing 
OMIM Online mendelian inheritance in man 
Pheo/Pheos Pheochromocytoma(s) 
PNET Pancreatic neuroendocrine tumor 
Pt Patient 
pVHL The VHL protein 
RCC Renal cell carcinoma 
SE Standard error 
SNOMED The systematized nomenclature of medicine 
TGF- Transforming growth factor  
US Ultra sound 
VEGF Vascular endothelial growth factor 
vHL von Hippel-Lindau disease 
VHL The VHL gene 
VUS Variant of unknown significance 
95% CI 95% Confidence interval 
SUMMARY 
von Hippel-Lindau disease (vHL) is a hereditary tumor predisposi-
tion caused by mutations in the VHL tumor suppressor gene. VHL 
mutation-carriers are at life-long risk of multi-organ tumor devel-
opment. The mainstay of vHL management is close surveillance 
and surgical tumor removal. The disease has been reported to be 
fully penetrant at 60 years of age, and has a highly variable phe-
notype, which complicates vHL management and causes distress 
and uncertainty for affected families. vHL survival has historically 
been poorer than the survival of the general population, with a 
median life expectancy for vHL patients of  only 49 years. vHL life 
expectancy is expected to be improved by better surveillance, tu-
mor diagnosis, and treatment approaches, although this has not  
 
 
yet been directly demonstrated. The prevalence of vHL is be-
tween 1 in 39,000 and 1 in 91,000 individuals, and the birth inci-
dence is between 1 in 36,000 and 1 in 45,500 live births in differ-
ent populations. Based on these estimates, vHL is underdiagnosed 
in Denmark, and many undiagnosed families are not offered ge-
netic counseling or prophylactic surveillance. 
We aimed to assess 1) how the rate of new manifestation devel-
opment is influenced by age, sex, genotype, tumor location, and 
pregnancy, 2) how vHL survival has developed over time, and is 
affected by sex, genotype, and surveillance attendance, 3) to de-
termine the prevalence and incidence of vHL, and 4) to calculate 
vHL penetrance based on an unselected national cohort. 
We including almost all diagnosed vHL patients in Denmark in a 
retrospective cohort study. We further used the national health 
registers to find individuals who had a missed vHL diagnosis de-
spite fulfilling the clinical diagnostic criteria.  
We found that the risk of new vHL manifestations varies with age, 
genotype, and tumor location. The risk of new retinal tumors is 
highest in the patients’ teenage years, while cerebellar tumors 
developed at the highest rates in patients’ thirties. Patients with 
truncating mutations had higher rates of new manifestation diag-
nosis than patients with missense mutations. Men tend to have 
higher manifestation rates in adulthood compared to women, 
and pregnancy was associated with a lower frequency of new 
manifestations. vHL survival has improved over time, and is get-
ting closer to that of their siblings without vHL and the general 
population. Survival is significantly influenced by a patient’s birth 
year, sex, and genotype. We estimate the mean life expectancy of 
VHL mutation-carriers born in 2000 to be 67 years for men and 60 
years for women.  
We estimate the vHL prevalence to be about 1 in 46,900 individu-
als and the birth incidence to be about 1 in 27,300 live births. We 
found a penetrance at age 60 of 87%, and only 80% among pa-
tients who have not attended surveillance prior to diagnosis, 
which is considerably lower than previous estimates.  
 Our findings form the basis of a more targeted vHL surveillance 
and counseling. The lower age-related penetrance greatly influ-
ences risk assessment in a clinical genetic setting. Even though 
the prevalence has increased over recent years, vHL is still under-
diagnosed, and there is a need for increased awareness about the 
disease. 
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